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Abstract 
 
Nanotechnology has gained importance in the past years as it provides opportunities for industrial growth and innovation. 
However, the increasing use of manufactured nanomaterials (NMs) in a number of commercial applications and consumer 
products raises also safety concerns and questions regarding potential unintended risks to humans and the environment. 
Since several years the European Commission’s Joint Research Centre (JRC) is putting effort in the development, 
optimisation and harmonisation of in vitro test methods suitable for screening and hazard assessment of NMs. Work is 
done in collaboration with international partners, in particular the Organisation for Economic Co-operation and 
Development (OECD). This report presents the results from an interlaboratory comparison study of the in vitro Colony 
Forming Efficiency (CFE) cytotoxicity assay performed in the frame of OECD's Working Party of Manufactured 
Nanomaterials (WPMN). Twelve laboratories from European Commission, France, Italy, Japan, Poland, Republic of Korea, 
South Africa and Switzerland participated in the study coordinated by JRC. The results show that the CFE assay is a 
suitable and robust in vitro method to assess cytotoxicity of NMs. The assay protocol is well defined and is easily and 
reliably transferable to other laboratories. The results obtained show good intra and interlaboratory reproducibility of the 
assay for both the positive control and the tested nanomaterials.  
In conclusion the CFE assay can be recommended as a building block of an in vitro testing battery for NMs toxicity 
assessment. It could be used as a first choice method to define dose-effect relationships for other in vitro assays. 
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Executive summary 
The European Commission's Joint Research Centre (JRC) provides scientific support to 
European Union policies, including nanotechnology. Nanotechnology has gained importance 
in the past years, it provides opportunities for industrial growth and innovation, and has an 
enormous potential to solve future challenges to the society. Nanotechnology innovation 
will be seen in many sectors including public health, employment, occupational safety and 
health, information society, industry, innovation, environment, energy, transport, security 
and space. However, the increasing use of manufactured nanomaterials (NMs) in a number 
of commercial applications and consumer products raises also safety concerns and 
questions regarding potential unintended risks to humans and the environment. Since 
several years the JRC is putting effort in the development, optimisation and harmonisation 
of test methods suitable for hazard assessment of NMs. International harmonisation of 
these test methodologies is ensured, among others, through JRC’s participation in the 
Organisation for Economic Co-operation and Development (OECD) Working Party of 
Manufactured Nanomaterials (WPMN). The OECD WPMN’s programme on the safety of 
manufactured NMs addresses all the different components including the availability of 
adequate methods needed for thorough manufactured NMs risk assessments. One of the 
objectives of this programme is to explore the potential application of alternative (in vitro) 
methods for testing of manufactured NMs.   
This report presents the results from an interlaboratory comparison study of the Colony 
Forming Efficiency cytotoxicity assay performed in the frame of the OECD WPMN. The 
Colony Forming Efficiency (CFE) assay is a label-free method for the assessment of basal 
cytotoxicity. Being non-colorimetric and non-fluorescent the method avoids possible 
interferences of NMs with the toxicity assessments. The CFE assay has been optimised and 
standardised for NMs testing by the JRC’s Nanobiosciences Unit. The aim of this project was 
to evaluate intra and interlaboratory reproducibility of the CFE assay, to identify possible 
factors that could influence results and to propose measures to increase harmonisation of 
the protocol used for testing NMs. Twelve laboratories from European Commission, France, 
Italy, Japan, Poland, Republic of Korea, South Africa and Switzerland participated in the 
study. A positive control (sodium chromate) and 9 NMs were tested. The results of the study 
show that the CFE assay protocol is easily and reliably transferable to other laboratories. 
The intra and interlaboratory reproducibility of the CFE assay was good with a percentage of 
Coefficient of Variation (CV %) less than 20% for the intralaboratory and less than 30% for 
the interlaboratory variation. We conclude that the CFE assay is a suitable method to assess 
cytotoxicity of NMs and has several advantages over commonly used in vitro  cytotoxicity 
assays (e.g. MTT, Lactate Dehydrogenase (LDH) release, Neutral Red Uptake, etc.), as it 
allows avoiding test interferences while being often more sensitive. The assay was 
considered useful as an early screening method. It could be also used in combination with 
other in vitro assays to define the subtoxic doses for further in vitro testing.  
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1. Introduction 
Nanomaterials (NMs) are used in a variety of industrial sectors and in numerous consumer 
products, such as paint, catalysts, sports items, surface treatment products, textiles, cosmetic 
products, food additives and packaging, vehicle tyres, electronic items and analytical chemical 
equipment. Some applications are new, while others, such as paint and catalysts, have been 
around for many years.  
According to the European Commission’s Recommendation on the definition of a 
nanomaterial adopted in 2011 a “Nanomaterial means a natural, incidental or manufactured 
material containing particles, in an unbound state or as an aggregate or as an agglomerate 
and where, for 50 % or more of the particles in the number size distribution, one or more 
external dimensions is in the size range 1 nm - 100 nm” ( EU 2011).  
NMs are not intrinsically hazardous per se but there may be a need to take into account 
specific considerations in their risk assessment. They are often well-known chemical 
substances that demonstrate new physical and chemical characteristics when in nano form. 
Gold, for example, is known for being very inert but if produced in nano form, it changes 
colour, reacts chemically, and can even be used to catalyse chemical reactions. Other 
examples of new characteristics materials may possess in nanoscale are electrical conductivity 
and magnetic properties. The enormous complexity of nanotechnology comes from the fact 
that the same chemical substance can be used in a variety of different nano forms that have 
wide range of properties including size, shape, surface functionalization, surface charge, that 
affect drastically their way of interacting with biological systems such as biological fluids 
(protein interactions) and living cells (cellular uptake, mechanisms of toxic response). This 
renders their safety assessment a real challenge. 
Nanotechnology is a quickly developing field and it is expected that a large number of new 
NMs will be produced and put to use in the near future. To enable a quick and reliable safety 
assessment of these NMs used in consumer products, there is an urgent need to provide 
robust, standardized test methods for toxicity screening. 
In vitro test methods are an essential tool for toxicity testing of NMs. They are used for basic 
research in mechanistic toxicity studies, for toxicity screening purposes, as well as for 
regulatory testing. However, some properties of materials in nano form can hinder the 
outcome of an experiment through assay interference, leading to a risk of false positive or 
false negative results. Recent research has shown that a good knowledge of the physico-
chemical characteristics of the NMs being tested is essential. Each NM may pose specific 
challenges especially in terms of sample preparation and dosimetry. The assessment of NMs 
toxicity in vitro has to consider the NMs physicochemical characterisation of the stock 
suspensions measured by different analytical techniques, physicochemical characterisation of 
NMs behaviour in biological media (e.g. cell culture medium) and NMs interaction with 
proteins. The possible interactions between the NMs and the assay systems should be 
systematically analysed. Some problems reported in the literature include interference of 
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NMs with optical detection methods (light absorption, fluorescence), chemical reaction 
between the NMs and the in vitro assay components, adsorption of assay molecules (e.g. 
antibodies, enzymes) on the particle surface (Casey et al., 2007; Kroll et al. 2012; Han et al., 
2011; Holder et al., 2012; Monteiro-Riviere et al., 2009; Oostingh et al., 2011; Stone et al., 
2009). Therefore, the conventional and well-established in vitro assay protocols used to test 
chemicals or pharmaceuticals should be employed with caution and adapted when applied for 
NMs. Consequently, there is a need to develop and standardize novel, well-controlled and 
possibly label-free in vitro methods, with reduced possibility of interferences between NMs 
and the assays readouts.  
Since several years, the JRC is working on the development and optimization of in vitro test 
methods suitable for hazard assessment of NMs. As part of this effort, existing in vitro test 
methods are adapted for NMs testing, by introducing appropriate controls to account for 
potential artefacts resulting from interaction of NMs with the assays. This work is done in 
close collaboration with the OECD WPMN (http://www.oecd.org/science/nanosafety).  
Under the OECD WPMN, the Sponsorship Programme for the Testing of Manufactured 
Nanomaterials was launched to investigate an agreed set of representative MNMs using 
appropriate test methods, preferably the OECD Test Guidelines, for a number of endpoints 
relating to physico-chemical characterisation, human health and environmental safety. The 
need for adaptation of existing Test Guidelines for the purpose of NMs testing is also being 
assessed. 
Based on the work of the WPMN, the OECD Council issued a recommendation  (C(2013)107 
from September 2013) stating that in the testing of manufactured NMs current OECD Test 
Guidelines should be applied and adapted as appropriate to take into account the specific 
properties of manufactured NMs in the testing of these materials. The recommended tools 
for the adaptation of the existing chemical regulatory frameworks or other management 
systems to the specific properties of manufactured NMs include two documents: Preliminary 
Review of OECD Test Guidelines for their Applicability to Manufactured Nanomaterials 
[ENV/JM/MONO(2009)21] and Guidance on Sample Preparation and Dosimetry for the Safety 
Testing of Manufactured Nanomaterials [ENV/JM/MONO(2012)40].  
Within its objectives, the WPMN aims also at exploring specific applications of in vitro 
methods to manufactured NMs including the use of existing alternative methods that could 
be incorporated in harmonized testing approaches. In a series of OECD WPMN Expert 
Consultation Meetings on Alternative Test Methods in Nanotoxicology, several in vitro 
methods have been identified as particularly relevant for hazard assessment of NMs and 
sufficiently developed to be proposed for round-robin and/or validation studies, and possible 
future adaptation in Test Guidelines. These include methods for assessing cytotoxicity (Colony 
Forming Efficiency assay), genotoxicity (in vitro micronucleus test, Comet assay), 
mutagenicity, as well as in vitro models for biokinetic studies and methods for topical toxicity 
assessment (skin and eye tolerance).  
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One of the methods that have been successfully adapted and standardised by the European 
Commission (EC) JRC Nanobiosciences Unit for the assessment of basal cytotoxicity of NMs is 
the label-free Colony Forming Efficiency assay. In June 2012 the WPMN officially included in 
its work plan a project on the interlaboratory comparison of the CFE assay.  
This report presents the results and conclusions from the CFE interlaboratory comparison 
study. Chapter 2 outlines the study design and its organisation. A detailed description of the 
CFE assay is presented in Chapter 3. Information about the synthesis and physico-chemical 
characterisation of the NMs used during the project is given in Chapter 4. The statistical 
approach used for the analysis of the CFE assay results, i.e. calculation of Inhibitory 
Concentration (IC50) values and assessment of intra and interlaboratory variability, is 
presented in Chapter 5. Chapter 6 describes and summarises the results obtained from the 
CFE assay in all laboratories for each of the NMs tested and provides an analysis of the assay 
reproducibility. The conclusions from the study are presented in Chapter 7.  A list of 
abbreviations has been included before the Introduction. Furthermore, the protocols used for 
cell culturing and for performing the CFE assay are given in Appendices 1 and 2.  
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2. Organisation of the interlaboratory comparison study 
The main objectives of the interlaboratory comparison study were:  
• To evaluate the suitability of the CFE assay for cytotoxicity screening of NMs 
• To assess the transferability, intralaboratory and interlaboratory reproducibility of the 
CFE assay   
• To identify possible factors that influence results 
• To propose measures to further increase harmonisation of the assay protocol 
• To deliver a final protocol for the assay suitable for testing a large range of NMs. 
The project was officially included in the OECD WPMN work plan in June 2012. The study 
started in September 2012 and was coordinated by the JRC. A total of twelve laboratories 
from Europe, Japan, South Korea and South Africa participated in this work (see Table 2.1).  
JRC was in charge of the experimental design of the study, prepared a detailed project plan, 
performed the selection, synthesis and physicochemical characterisation of all tested NMs 
(except single walled carbon nanotubes (swCNT) that were synthesised, characterised and 
provided to all labs by AIST, Japan), supplied the participants the Standard Operating 
Procedures (SOPs, see Appendix 1 and 2 to this report), the NMs and the cell line.  
The Madin Darby Canine Kidney (MDCK) cell line used in this project was selected based on its 
ability to form well-defined colonies that are relatively easy to count. All laboratories received 
a flask of cells in culture, from the same passage, and were asked to propagate and freeze a 
stock of the cells for the purpose of the study, according to a well-defined protocol (see 
Appendix 1).  
The selected NMs were gold nanoparticles (Au NPs, three sizes), silver nanoparticles (Ag NPs, 
two sizes) and silica nanoparticles (SiO2 NPs, two sizes), single-walled carbon nanotubes 
(swCNTs) and zinc oxide nanoparticles (ZnO NPs, one size) (Table 2.2). The physico-chemical 
characterisation of the NMs used during the project, including the stability testing, was 
performed at JRC and is extensively presented in Chapter 4 of this report. All the NMs were 
found to be stable for at least 6 months, except NPs code I (ZnO) that is unstable and had to 
be used within 15 days after suspension in aqueous media.  
A positive control (sodium chromate, Na2CrO4) and 9 NMs were tested in the CFE assay. Cells 
were exposed to selected concentrations of NMs and positive control for 72 h. In the first 
step, a complete dose-response range of sodium chromate (positive control) was tested by 
each laboratory. This step was used for training and problem-solving purposes. It also allowed 
evaluating the CFE protocol transferability to each laboratory. In the second step, all 9 NMs 
were tested in the 12 laboratories.  
The experimental part was concluded in May 2014. All the results (raw data) were submitted 
by the laboratories to JRC for analysis. The statistical analysis was carried out by an 
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independent statistician from an external company (StatBio, Enskild, Sweden). The approach 
used for the analysis is outlined in Chapter 5.   
 
Table 2.1. List of laboratories participating in the study 
Country Institution Acronym 
Laboratory 
number 
Japan National Institute of Advanced Industrial Science 
and Technology 
AIST 1 
France CEA Life Science Division CEA 2 
Switzerland Swiss Federal Laboratories for Materials Science 
and Technology 
EMPA 3 
Italy Italian National Agency for New Technologies, 
Energy and Sustainable Economic Development 
ENEA 4 
France Institut Pasteur de Lille IPL 5 
Italy Istituto Superiore di Sanità ISS 6 
European 
Commission 
Joint Research Centre, Institute for Health and 
Consumer Protection, Nanobiosciences Unit 
JRC 7 
Republic of 
Korea 
Korea Research Institute of Standards and 
Science 
KRISS 8 
Republic of 
Korea 
National Institute of Environmental Research NIER 9 
Republic of 
Korea 
National Institute of Food and Drug Safety 
Evaluation 
NIFDS 10 
South Africa National Institute for Occupational Health NIOH 11 
Poland Nofer Institute of Occupational Medicine NIOM 12 
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Table 2.2.  List of nanomaterial tested in the study  
NPs name 
Nominal 
size (nm) 
Batch number Supplier 
NPs code 
used in the study 
Au NPs 5 RLS 57 JRC in-house synthesis A 
Au NPs 35 RLS 70 JRC in-house synthesis B 
Au NPs 15 NM 330* JRC NMs Repository C 
Ag NPs 30 RLS 213 JRC in-house synthesis D 
Ag NPs 20 NM 300* JRC NMs Repository E 
swCNTs -  AIST F 
SiO2 NPs 20 I0102A JRC in-house synthesis G 
SiO2 NPs 90 I0102C JRC in-house synthesis H 
ZnO 240 NM110* JRC NMs Repository I 
* 
Starting from May 2014 the Repository Materials are named as follow: NM330 is JRCNM03300a; 
NM300 is JRCNM03000a and the corresponding dispersant is JRCPD03001a; NM110 is JRCNM01100a. 
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3. Colony Forming Efficiency Assay (CFE) 
3.1 Description of the assay 
The CFE is a clonogenic assay that measures the ability of a single cell to form a colony. This in 
vitro assay can be used to determine cytotoxicity induced by NMs. It can be performed with 
any adherent cells that are able to form colonies (e.g. Balb/3T3, MDCK, HaCaT, HepG2, A549). 
The CFE assay cannot be used with non-adherent cells or cells unable to form colonies. 
In the CFE assay the cells are seeded in a dish at a low cell density, treated with the 
investigated potential toxicant and cultured for several days to allow the formation of 
colonies. Changes in cell viability after treatment with a toxicant will result in a decreased 
number of colonies formed in comparison to the negative control (untreated cells) or solvent 
control (cells exposed to the solvent used for NMs synthesis and dispersion or for dissolution 
of chemicals). Cytotoxicity (inhibition of colony formation) is expressed as percentage of CFE 
with respect to the negative or solvent control.  
The conventional in vitro cytotoxicity tests widely used for testing soluble chemicals and drugs 
may be difficult to apply for NMs due to possible interferences of NMs with the assay 
readouts and/or the assay components. There are several problems that can arise when using 
in vitro  assays, including interference with optical detection methods (light absorption, 
fluorescence), chemical reaction between the NMs and the assay components, adsorption of 
assay molecules on the particle surface, shading effects (Kroll et al.., Casey et al.., 2007, 
Monteiro-Riviere et al.., 2009). The great advantage of the CFE assay is that it is a label-free 
test (non-colorimetric, non-fluorescent) that reduces the possibility of the occurrence of 
interferences. This test has already been used in different in vitro systems to assess 
cytotoxicity of a wide range of NMs e.g. gold NPs (Coradeghini et al., 2013), silver NPs 
(Locatelli et al., 2012), titanium oxide NPs (De Angelis et al., 2013; Fenoglio et al., 2013), zinc 
oxide NPs (De Angelis et al., 2013), silica NPs (Uboldi et al., 2012), or mwCNTs (Ponti et al., 
2010). By using this assay it is also possible to distinguish between cytotoxic effects (reduction 
of the number of colonies formed) or cytostatic effects (reduction in the colony area). In this 
interlaboratory comparison study, however, only the cytotoxic effects were assessed. 
The procedure used for performing the CFE assay in the present study is described concisely 
below and schematically presented in Figure 3.1. All methodological details can be found in 
the complete SOPs for the MDCK cell maintenance and for the CFE assay presented in 
Appendices 1 and 2, respectively.  
Briefly, on Day 1, 200 MDCK cells are seeded in 3 mL of fresh complete medium in 60-mm 
Petri dishes (six replicates per treatment condition). After 24 h (Day 2), the treatment 
suspensions of NMs (Table 3.1) and the positive control (Na2CrO4 • 6H20, 100 µM) are added 
to the cells. The cells are kept in contact with the treatment suspension for 72 h (from Day 2 
to Day 5), then on Day 5 the test compounds are removed and replaced with complete fresh 
medium and the cells are cultured for additional 3 days until Day 8. At the end of each 
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treatment (Day 8), the medium is removed; the colonies are first fixed using a solution of 4% 
(v/v) formaldehyde in PBS, then stained using 0.4% (v/v) of Giemsa in MilliQ water. After 
drying, colonies (composed of at least 50 cells) are counted under a stereomicroscope.  
The results are normalised to the negative control (cells exposed to fresh complete culture 
media) or solvent control (cell exposed to solvent used for NM synthesis or dispersion) and 
expressed as:  
% CFE = (average of number of colonies in treatment /average of number of colonies in 
negative control or solvent control) * 100.  
A reduction in the number of colonies formed in the treatment with respect to the negative 
or solvent control is a measure of cytotoxicity. 
 
 
 
 
Figure 3.1.  Schematic presentation of the protocol for the CFE assay. 
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Table 3.1.  Concentrations of NPs code A-E and G-I. The concentrations are expressed as 
µM, µg/mL (of Au, Ag, Si or Zn) and number of NPs/mL. The number of NPs was 
calculated based on size distribution obtained from Centrifugal Liquid 
Sedimentation (CLS) measurements. Note that for NPs code F (swCNTs) 
concentrations were expressed only in µg/mL and three concentrations were 
tested: 1, 10 and 100 µg/mL. For each NM a solvent control corresponding to 
the solution in which NPs are dispersed was tested. For each NM the 
concentration of solvent was the same in each treatment suspension and 
corresponded to the concentration present in the highest dose tested. 
  
 
NPs concentrations tested 
(µM) (µg/mL)  Number of NPs/mL 
A – B - C A – B – C  A B C 
1 0.20  3.28E+11 7.29E+08 1.16E+10 
5 0.98  1.64E+12 3.64E+09 5.78E+10 
10 1.97  3.28E+12 7.29E+09 1.16E+11 
50 9.85  1.64E+13 3.64E+10 5.78E+11 
100 19.70  3.28E+13 7.29E+10 1.16E+12 
200 39.93  6.57E+13 1.46E+11 2.31E+12 
300 59.09  9.85E+13 2.19E+11 3.47E+12 
400 78.78  1.31E+14 2.92E+11 4.62E+12 
D – E D – E  D E  
0,1 0.01  1.06E+08 1.19E+09  
0,5 0.05  5.32E+08 5.96E+09  
1 0.11  1.06E+09 1.19E+10  
1,5 0.16  1.60E+09 1.79E+10  
2,5 0.27  2.66E+09 2.98E+10  
3,5 0.38  3.72E+09 4.17E+10  
5 0.54  5.32E+09 5.96E+10  
10 1.08  1.06E+10 1.19E+11  
G – H G – H  G H  
16,6 1  7.79E+10 1.98E+09  
166,4 10  7.79E+11 1.98E+10  
1664,3 100  7.79E+12 1.98E+11  
I I  I   
1 12.3  5.23E+04   
10 123.0  5.24E+05   
15 184.2  7.84E+05   
20 245.6  1.05E+06   
22,5 276.3  1.18E+06   
25 307.0  1.31E+06   
50 614.0  2.61E+06   
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3.2   Catalogue of images of colonies formed by MDCK cells 
During the course of the project images of representative colonies formed by MDCK cells and 
observed under the stereomicroscope were collected. This catalogue of images is an 
important tool providing instructions for counting of colonies obtained in the CFE assay. 
When establishing the CFE protocol in a laboratory one has to be aware of possible problems 
that can occur (e.g. related to wrong cell seeding) and which may influence the colony 
formation and/or the colony counting and thus change the final result of the assay. Examples 
of such typical errors were also included in the image catalogue.  
Figure 3.2 A-C shows representative colonies obtained after the treatment with the negative 
control in the case of a correct cell seeding (Figure 3.2 A) or when an error in the calculation 
of cells to be seeded occurs (Figure 3.2 B and C). When the number of cells seeded is higher 
than needed, colonies are overlapping and it is not possible to distinguish them between each 
other, which compromises the counting (Figure 3.2 B). In case of a too low cell seeding 
density (Figure 3.2 C), not enough colonies are formed and the test results are not acceptable 
(according to acceptance criteria defined in the SOP, see Appendix 2). A lower number of 
colonies could be also due to an error in mixing the cell suspension before or during the 
seeding, or to bacterial or mycoplasma contamination of the cell culture.  
Figure 3.2 D shows a negative control with good cell colonies formed but with an empty zone 
in the dish (highlighted with a dashed line) where cells were not able to attach and 
proliferate. This phenomenon occurs randomly and could be due to a failed treatment of the 
cell culture dishes during production, or if the dish was not swirled efficiently after cell 
seeding leaving a dried space on the surface which prevented the attachment of cells.  
 
Figure 3.2.  Examples of MDCK cell colonies. The images represent colonies in the negative 
control at the end of the CFE assay in (A) correct conditions, (B) when the 
number of cells seeded is higher or (C) lower than the required one (200 
cells/dish). A situation where the number of colonies formed is correct but a 
part of the dish is free of colonies is shown in (D). 
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Single colonies can also have a different morphology and density as reported in Figure 3.3. 
Colony nr 1 has a cell density typical for MDCK cells; colony nr 2 and 3 are less dense and 
single cells can be distinguished. Colony number 4 and 5 represent a mix of the two situations. 
However, all these colonies have a well-defined perimeter and contain more than 50 cells (see 
acceptance criteria in the SOP, Appendix 2). 
 
 
 
Figure 3.3.  Different morphology and cell density of single colonies formed by MDCK cells 
after 8 days of culture (negative control treatment).  
 
During their growth colonies can sometime overlap making the colony counting difficult; 
some examples are shown in Figure 3.4. The dashed lines encircle the perimeter of the 
colonies. Examples nr 1 and nr 3 show two overlapping colonies but with a well-defined 
center. In examples nr 2 and 4, three colonies are overlapping. Example nr 5 is difficult to 
analyse since the centers of the colonies are not well-defined. In this case one, two (as 
suggested here by dashed lines) or even three colonies could be counted. In the example nr 6 
one could consider counting two colonies, but since the division between them is not evident 
and the two cannot be easily distinguished, we count it as only one colony. Example nr 7 
shows two colonies of different cell density with well-defined centers. Finally, in the example 
nr 8 six colonies are counted since the perimeter of all of them can be well defined. 
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Figure 3.4.  Examples of colonies that can be formed by MDCK cells; colonies are defined 
by dashed lines. Examples show overlap of two colonies (nr 1, 3 and 5); overlap 
of three colonies (nr 2 and 4); single colonies with different cell density (nr 6 
and 7), and six overlapping colonies (nr 8).   
 
Images of colonies presented in Figure 3.4 were used in a small exercise that was aimed to 
evaluate differences in the colony counting between various laboratories and operators. Each 
laboratory was asked to count the colonies (images were provided to them without the 
dashed lines) and the results are presented in Figure 3.5.   
In most cases the laboratories counted the same number of colonies, with some exceptions in 
particular, in the case of examples nr 3, 5 and 8, where four/five laboratories among twelve 
counted significantly different number of colonies.  
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Figure 3.5. Differences in colony counting between various laboratories. Laboratories 
were asked to count and report the numbers of colonies presented in Figure 
3.4 (without dashed lines).  
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4. Nanomaterials synthesis, sourcing and physicochemical 
characterisation 
The materials used in this study were obtained by in-house synthesis (NPs code A, B, D, G, H), 
from the JRC repository of representative NMs (NPs code C, E, I) or supplied by AIST (NPs code 
F). In the case of the in-house synthesised materials the following sections detail the synthesis 
method and principle physicochemical characteristics of the materials as determined shorty 
after synthesis. In the case of the materials which were sourced from the JRC repository the 
synthesis routes are not detailed but physicochemical properties are reported.  
For the materials A-B-C-D-E-G-H it was also possible to verify the long term colloidal stability 
by conducting Centrifugal Liquid Sedimentation (CLS) and/or spectroscopic analysis on 
samples which have been held for 6 months under ideal conditions (4°C under inert 
atmosphere and away from prolonged light exposure). 
The swCNT (code F) were supplied by AIST. ZnO NPs (code I) were initially in dry powder but 
the characterisation refers to the materials after re-dispersion into biocompatible solvents.  
Stock suspensions of each NP were characterised using different techniques such as 
Transmission Electron Microscopy (TEM), Dynamic Light Scattering (DLS), CLS. The main 
particle size and surface charge characteristics are summarised in Table 4.4 at the end of this 
chapter. 
 
4.1 Description of characterisation methods 
4.1.1 Transmission Electron Microscopy  
TEM analysis of the liquid dispersed particles was done following liquid spotting on copper 
support grids. A drop of undiluted product (4 µL) was placed onto ultrathin Formvar-coated 
200-mesh copper grids (Tedpella Inc.) and left to dry in air at 4°C. For each sample, the sizes 
of at least 100 particles were measured to obtain the average and the size distribution. NPs 
were visualized using TEM (JEOL 2100, Japan) at an accelerating voltage of 200 kV. Digital 
images were analysed with the ImageJ software and a custom macro performing smoothing 
(3x3 or 5x5 median filter), manual global threshold and automatic particle analysis provided 
by the ImageJ.  
4.1.2 DLS and Zeta-potential measurement of NPs  
Particle size distribution was determined by DLS using a Zetasizer Nano-ZS instrument 
(Malvern Instruments Ltd, UK) with temperature control (25°C). Each sample was recorded in 
duplicate with an equilibration step of 120 sec. Acquisition time was 80 sec. Software was set 
to automatic acquisition mode. Hydrodynamic diameters were calculated using the internal 
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software analysis from the DLS intensity-weighted particle size distribution. Z-potential was 
measured using the same instrument and recorded in a DTS1060C disposable cell with an 
equilibration time of 120 sec. Measurements were done just after pH measurement using a 
Smulochowski model with a F(Ka) of 1.5. 
4.1.3 CLS measurement of NPs  
In order to assess the particle size distributions of the nanoparticles CLS measurements were 
performed on the as synthesised nanoparticle dispersions. Measurements were made using a 
CLS instrument (model DC24000UHR CPS Instruments) in an 8 wt% - 24 wt% sucrose density 
gradient with a disc speed of 22.000 rpm. Each sample injection of 100 µL was preceded by a 
calibration step performed using certified poly(vinyl chloride) (PVC) particle size standards 
with mean size of 380 nm. 
 
4.2 Gold NPs by in-house synthesis (NPs code A and B) and 
sourced from JRC repository (NPs code C) 
The synthesis of Au NPs code A sodium citrate stabilised (2.5 mM of sodium citrate at pH 6.7) 
was carried out by reduction of gold (III) chloride trihydrate salt with the strong reducing 
agent sodium borohydrate (NaBH4). Briefly, 95 mL of MilliQ water were stirred in an ice bath 
for 2 h. Then 5 mL of aqueous solution of gold (III) chloride trihydrate (10 mM) and 2.5 mL of 
trisodium citrate dihydrate (100 mM) were added to the water solution during the stirring. 
Afterwards, 1 mL of aqueous sodium borohydrate (100 mM) was added to the solution under 
vigorous stirring. The reduction of gold salt to gold nanoparticles by the NaBH4 produced a 
change in colour of the solution from pale yellow to dark red. The suspension was then stirred 
in the ice bath for further 10 min and then left to warm to room temperature. The nominal 
concentration calculated by the stoichiometry was 0.5 mM.  
For the biological testing, NPs code A were concentrated by centrifugal ultrafiltration using 
AMICON ULTRA-15 10KDa filter tubes (Millipore, Milan, Italy). 10 mL NPs code A suspension 
was added on each filter and tubes were centrifuged for 20 min at 1500 rcf at room 
temperature during which time the sample volume was reduced from 10 mL to 1.2 mL. The 
real final concentration measured by Inductively Coupled Plasma Mass Spectrometry (ICP-MS, 
Agilent Technologies Inc., 7700 series, USA) was 4.25 mM. Stock suspension was stored at 4°C 
in dark remaining stable in terms of size distribution for at least 6 months. 
The synthesis of NPs code B was carried out by a two-step seed growth method in which the 
reduction of gold (III) chloride hydrate salt in the presence of trisodium citrate dihydrate was 
used to selectively enlarge highly mono-dispersed 12 nm size gold seed particles. In the first 
step of the process, the 12 nm seed particles were obtained by a method adapted from that 
described by (Turkevich et al.., 1951). Briefly, the solution was heated up using a microwave 
apparatus (Discover S by CEM corporation) to ensure a highly reproducible rapid heating. In 
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this method, 5 mL of 10 mM tetrachloroauric acid trihydrate (HAuCl4 x 3H2O) was dissolved in 
95 mL of water. The solution was rapidly heated up and held at 97°C for 5 min using a 
microwave power of 250 W under vigorous mechanical stirring; 2.5 mL of 100 mM trisodium 
citrate dihydrate was added to the solution and kept at 97°C for another 20 min. Afterwards, 
the solution was rapidly cooled down to 40°C and then to room temperature. The gold 
nanoparticles were produced by the reduction of the gold salt by sodium citrate that acted as 
both reducing agent and stabilizer. The final solution contained 12 nm size gold nanoparticles 
with 0.5 mM of gold NPs stabilized with 2.5 mM of sodium citrate at pH 6.7. 
In the second stage of the synthesis, 95 mL of MilliQ water were left to stir at 60°C for 2h. 2.8 
mL of sodium citrate dihydrate (100 mM) and 0.42 mL of 200 mM sodium hydroxide were 
added to the citrate solution and left to equilibrate for 30 min. Then, 2.24 mL of 
tetrachloroauric acid trihydrate 10 mM (HAuCl4 x 3H2O) and 0.6 mL of 12 nm gold 
nanoparticles with a gold NPs concentration of 0.5 mM were added to the solution, under 
vigorous stirring. The solution was left to react for 48 h at 60°C. The final solution contained 
NPs code B with 0.25 mM of gold NPs stabilised with 2.8 mM of sodium citrate at pH 6.7. The 
nominal concentration calculated was 0.25 mM. 
For the biological testing, NPs code B were concentrated by centrifugal ultrafiltration using 
the AMICON 10KDa filter tubes (Millipore, Milan, Italy); 10 mL NPs code B suspension was 
added on each filter and tubes were centrifuged for 20 min at 1500 rcf at room temperature. 
The final concentration was measured by ICP-MS and found to be 4 mM. This stock 
suspension, when stored at 4°C away from light, will normally maintain a stable particle size 
distribution for at least 6 months. 
The NPs code C was a representative nanomaterial (NM330) stored in the JRC-Repository: The 
as-supplied material was initially at the concentration of approximately 0.25 mM, as 
measured by UV-Vis. For the biological testing, NPs code C were also concentrated using the 
AMICON 10KDa filter tubes (Millipore, Milan, Italy). 10 mL NPs code C suspension were added 
on each filter and tubes were centrifuged for 20 min at 1500 rcf at room temperature. The 
real final concentration measured by ICP-MS was 1 mM. The stock suspension was stored at 
4°C in dark, remaining stable in terms of size distribution for at least 6 months. 
4.2.1 CLS and UV-Vis characterisation of Au NPs 
The particle size distributions of the Au NPs were determined in the stock suspension as-
synthesised, after concentration and after long term storage. For CLS and UV-Visible (UV-vis) 
analysis, the samples were diluted 1:10 in solvent controls. The results of the CLS analyses are 
shown in  
Figure 4.1, Figure 4.2 and Figure 4.3. The UV-vis spectroscopic analysis results are presented 
in Figure 4.4, Figure 4.5 and Figure 4.6, while the numerical data are reported in Table 4.1. 
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Figure 4.1.  CLS analysis of Au NPs code A stock suspension 
 
Figure 4.2.  CLS analysis of Au NPs code B stock suspension 
 
Figure 4.3.  CLS analysis of Au NPs code C stock suspension 
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Figure 4.4.  UV-vis spectroscopic analysis of Au NPs code A stock suspension 
 
Figure 4.5.  UV-vis spectroscopic analysis of Au NPs code B stock suspension 
 
Figure 4.6.  UV-vis spectroscopic analysis of Au NPs code C stock suspension 
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Table 4.1. Size distributions of NPs code A, B and C measured by CLS. The stock 
suspensions were diluted 1:10 in solvent controls. Measurements were done in 
the stocks before concentration, immediately after concentration and 6 
months after concentration. 
Size distribution by CLS (nm/HHW
1
/PdI
2
) 
NPs code 
Stock suspension as 
synthesised 
Stock suspension 
after concentration 
process 
Stock suspension 
after concentration 
and 6 months of 
storage 
A 3.9/1.7/1.2 3.3/0.9/1.8 3.1/0.3/1.1 
B 29.9/5.9/1.1 30.3/5.8/1.1 29.9/7.3/1.1 
C 11.9/1.4/1.2 12/1.5/1.4 10.5/1.5/1.69 
1 
Half Height Width (HHW) 
2
CLS Polydispersivity Index expressed as the ratio Dw/Dn where the Dw is the  average particle size 
calculated from the particle weight-size distribution while Dn is the average particle size calculated 
from the equivalent number-size distribution.  
The result of both CLS and UV-Vis spectroscopy show that all the gold NPs have good long 
term colloidal stability with no notable changes in either size or concentration occurring 
during a period of up to 6 months.  
 
4.3 Silver NPs by in-house synthesis (NP code D) and sourced 
from JRC repository (NP code E) 
The synthesis of NPs code D was carried out by reduction of silver nitrate salt with sodium 
citrate and tannic acid. Briefly, 6 mL of sodium citrate (28 mM) and 120 µL of tannic acid (2.24 
mM) were stirred at 60°C for 15 min; then 5 mL of this solution were added to 95 mL of (0.57 
mM) silver nitrate under boiling condition and vigorous stirring and kept at 97°C for further 40 
min. The solution was heated up using a microwave synthesis reactor (Discover S by CEM 
corporation) to ensure a highly reproducible and rapid heating. On completion of the reaction 
the solution was cooled rapidly with compressed air down to 40°C and then by natural 
convection to room temperature. The final suspension contained NPs code D stabilized with 
14 mM of sodium citrate and 2.7 µM of tannic acid at pH 6.8. 
The nominal concentration calculated by the stoichiometry was 0.5 mM and corresponded to 
the real one measured by ICP-MS (Agilent Technologies Inc., 7700 series, USA). Stock 
suspension was stored at 4°C in dark remaining stable in terms of size distribution for at least 
6 months. 
In order to obtain the solvent control for biological testing, the NPs code D were filtered using 
the AMICON ULTRA-15 filter tubes by centrifugation for 15-10 min. at 1500 rcf (Millipore, 
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Milan, Italy). After centrifugation the NPs were disposed and the filtrate used as solvent 
control. 
The Ag NPs code E were sourced from the JRC NMs repository (NM300) where they are 
stored in the form of a highly concentrated liquid dispersion containing 4% w/w of 
Polyoxyethylene Glycerol Trioleate and 4% w/w of Polyoxyethylene (20) Sorbitan Mono-
Laurate (Tween 20). ICP-MS elemental analysis of the as-supplied silver dispersion revealed 
that the total silver concentration is 940 mM. Vial containing the same aqueous mixture of 
NM300 dispersants (NM300DIS) but without the presence of any silver was used as solvent 
control. 
 
4.3.1 CLS and UV-Vis analysis of silver NPs code D and E 
The particle size distributions of the Ag nanoparticles were determined in the stock 
suspensions as-synthesised, and after long term storage. The results of the CLS analyses are 
shown in Figure 4.7 and Figure 4.8. The UV-vis spectroscopic analysis results are presented in 
Figure 4.9 and Figure 4.10. 
 
 
 
Figure 4.7.  CLS analysis of Ag NPs code D stock suspension 
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Figure 4.8.  CLS analysis of Ag NPs code E stock suspension 
 
Figure 4.9.  UV-Vis spectroscopic analysis of Ag NPs code D stock suspension 
 
Figure 4.10.  UV-Vis spectroscopic analysis of Ag NPs code E stock suspension 
 
The results of both CLS and UV-Visible spectroscopy show that the particles have good long 
term colloidal stability with no notable changes in either size or concentration occurring 
during a period of up to 6 months. 
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Table 4.2. Size distributions of NPs code D and E measured by CLS. The stock 
suspensions were diluted 1:10 in solvent controls. Measurements were done in 
the stocks and 6 months after synthesis. 
Size distribution by CLS (nm/HHW
1
/PdI
2
) 
NPs code 
Stock suspension as 
synthesised 
Stock suspension after 6 months of 
storage 
D 26.9/5.8/1.2 27.4/5.9/1.19 
E 12.1/3/1.2 11.9/2.8/1.45 
1 
Half Height Width (HHW) 
2
CLS Polydispersivity Index expressed as the ratio Dw/Dn where the Dw is the  average particle size 
calculated from the particle weight-size distribution while Dn is the average particle size calculated 
from the equivalent number-size distribution.  
 
4.4 swCNTs (code F) 
NPs code F were obtained from the Technology Research Association for swCNTs (Japan) and 
supplied for this project by AIST (Japan). The synthesis and physicochemical characterisation 
was performed at AIST and is described in detail in Fujita et al.. (2013).  
Impurity-free NPs code F were synthesised by water-assisted chemical vapour deposition 
(CVD). A highly efficient synthesis of NPs code F with high purity was enabled by adding a 
small and controlled level of water to the growth ambient (Hata et al.., 2004). This high 
efficiency resulted in a massive growth of vertically aligned swCNT (forest) from the catalyst 
surface. swCNT forests possess high-purity carbon, alignment and near-ideal specific surface 
area, and they can be patterned into arbitrary structures for applications ranging from super-
capacitors to stretchable electronics. 
NPs code F stock suspension was prepared in a 10 mg/mL BSA solution using an ultrasonic 
homogenizer for 30 min. After ultrasonic treatment, the dispersion was centrifuged at 3000 x 
g at 15°C for 15 min. The supernatant was filtered using a cell strainer with a 70 mm nylon 
mesh (Becton Dickinson & Company) and centrifuged at 22.000 x g at 10°C for 10 min. The 
precipitates were re-dispersed in a 10 mg/mL BSA solution using an ultrasonic bath operating 
for 5 min (Branson Ultrasonics Corp.). The mixtures were filtered using a cell strainer with a 
100 mm nylon mesh (Becton Dickinson & Company).  
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4.5 In-house synthesised silica NPs code G and H 
 
The NPs code G were synthesised using a method adapted from (Hartlen et al.., 2008). Briefly, 
cyclohexane (16.25 mL) was mixed with a solution of L-arginine (330 mg, 1.9 mmol) in milliQ 
water (250 mL). The mixture was heated to 50°C at a constant stirring rate of approximately 
300 rpm before tetraethyl orthosilicate (TEOS, 20 mL) was slowly added and the reaction was 
kept under these conditions for 24 h. 
The concentration of NPs code G in the stock suspension measured by gravimetric technique 
and provided to the partners was 3.2 mg/mL. The solvent control of NPs code G was obtained 
by ultrafiltration of nanoparticles suspension. The stock suspension was stored at 4°C in dark 
remaining stable in terms of size distribution for at least 6 months. 
 
Synthesis of NPs code H was done in two seeding-growth steps. In the first step, SiO2 NPs of 
30 nm were obtained by mixing 50 mL of as-synthesised SiO2 NPs of 20 nm with milliQ water 
(180 mL) and cyclohexane (25 mL), so that the total concentration of L-arginine was 1.5 mM. 
The mixture was heated to 50°C at a constant stirring rate of approximately 300 rpm before 
TEOS (18.5 mL) was slowly added and the reaction was kept under these conditions for 24 
hours. The same reaction conditions were used for the synthesis of SiO2 NPs of 75 nm by 
mixing 20 mL of as-synthesised SiO2 NPs of 30 nm with cyclohexane (10 mL) and a solution of 
L-arginine (12 mg, 0.07 mmol) in MilliQ water (72 mL), so that the total concentration of L-
arginine was 1 mM. The mixture was heated to 50°C at a constant stirring rate of 
approximately 300 rpm before TEOS (7.4 mL) was slowly added and the reaction was kept 
under these conditions for 24 h.  
The concentration of nanoparticles code H in the stock suspension measured by gravimetric 
technique and provided to the partners was 3.5 mg/mL. The solvent control of NPs code H 
was obtained by ultrafiltration of nanoparticles suspension. The stock suspension was stored 
at 4°C in dark remaining stable in terms of size distribution for at least 6 months. 
 
 
4.5.1 CLS analysis of silica NPs   
The particle size distributions of the SiO2 nanoparticles were determined in the stock 
suspensions as-synthesised and after long term storage. The results of the CLS analyses are 
shown in Figure 4.11 and Figure 4.12 and the size distributions are presented in Table 4.3. 
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Figure 4.11.  CLS analysis of SiO2 NPs code G stock suspension as synthesised (red) 
and after 6 months (Blue) 
 
 
Figure 4.12.  CLS analysis of SiO2 NPs code H stock suspension as synthesised (red) 
and after 6 months (Blue) 
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Table 4.3.  Size distributions of NPs code G and H measured by CLS. The stock 
suspensions were diluted 1:10 in solvent controls. Measurements were done in 
the stocks immediately after synthesis and 6 months after synthesis. 
Size distribution by CLS (nm/HHW
1
/PdI
2
) 
NPs code 
Stock suspension as 
synthesised 
Stock suspension after 6 months of 
storage 
G 21/6.8/1.30 22.5/8.8/1.27 
H 71.4/6.5/1.30 73.2/8.2/1.02 
1 
Half Height Width (HHW) 
2
CLS Polydispersivity Index expressed as the ratio Dw/Dn where the Dw is the  average particle size 
calculated from the particle weight-size distribution while Dn is the average particle size calculated 
from the equivalent number-size distribution.  
4.6 Repository sourced Zinc Oxide NPs (code I) 
NPs code I were supplied in powder form by the JRC NMs repository (NM110). The stock 
suspension at the concentration of 2.56 mg/mL of NPs code I was prepared at the JRC by 
weighting 2.56 mg of powder on an analytical balance and then suspending the powder in 1 
mL of sterile MilliQ water. The suspension (1.5 ml volume) was sonicated for 15 min. using a 
Vial Tweeter sonicator UIS250v (250 watt, 24kHz; Amplitude 75, Cycle 0.5; Hielscher, 
Ultrasound Technology, Germany). 
NPs code I stock suspension is extremely unstable and it was recommended that the 3 runs of 
the CFE assay should be conducted within 15 days of receiving the materials. Before the cell 
exposure, the NPs code I stock suspension had to be treated with vortex for 3 min. using the 
vortex mixer at the highest speed available and with ultra-sonication for 7 min. using the 
ultrasonic bath at the highest power available. After these treatments the suspension should 
appear homogeneous. 
 
4.6.1 CLS analysis of Zinc Oxide NP Code I  
The particle size distributions of the ZnO nanoparticles were determined in the stock 
suspensions after dispersion. The results of the CLS analyses are shown in Figure 4.13.  
 
 
 
 
 
Figure 4.13.  CLS analysis of ZnO NPs code I stock suspension 
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4.7 Summary of morphology and sizing of all NPs stock 
suspensions 
TEM analysis was conducted on samples of all the NPs used in this study to determine the 
shape of the particles and to verify whether the results of particle size as derived from DLS 
and CLS measurements were representative of the single particles or aggregates. In all cases 
the TEM sample grids were prepared by grid-on-drop or drop-on-grid starting from aqueous 
dispersions of the particles. The DLS and CLS measurements were conducted as described 
above on stock dispersions of the NPs and the results obtained are summarised in Table 4.4.  
 
Table 4.4. Characterisation of size distribution (by TEM, DLS and CLS) and Z-potential of 
the stock suspensions NPs code A – I. Samples for analysis were diluted 1:10 in 
their respective solvent controls. 
 
NPs 
code 
Nominal 
size (nm) 
Size distribution 
Z-Potential 
(mV) ± SD  TEM 
(nm ± SD) 
DLS  
(nm /PdI
1
) 
CLS 
(nm/HHW
2
/PdI
3
) 
A 5 3.6 ± 0.8 16.6/0.5 3.3/0.9/1.8 -48 ± 1 
B 30 32 ± 3 34.8/0.2 30.3/5.8/1.1 -43 ± 1 
C 15 13 ± 1 28.8/0.535 12/1.5/1.4 -43 ± 1 
D 30 28 ± 4 14.5/0.548 26.9/5.8/1.2 -33 ± 1 
E 20 14± 6 27.1/0.49 12.1/3/1.2 -10 ± 1 
F - 274.6 x 1.70 µm 763.6/nd nd -13.4 ± 0.3 
G 20 19.6 ± 7.1 26.8 / 0.012 21/6.8/1.30 - 33.0 ± 1.5 
H 75 76.8 ± 3.8 116.8 / 0.156 71.4/6.5/1.30 - 28.0 ± 2.1 
I 240 287.04 ± 169.75 230.2/0.168 187/144/9.9 32 ± nd 
1
DLS Polydispersivity Index 
2
Half Height Width (HHW) 
3
CLS Polydispersivity Index expressed as the ratio Dw/Dn where the Dw is the  average particle size 
calculated from the particle weight-size distribution while Dn is the average particle size calculated 
from the equivalent number-size distribution.  
nd: not determined. 
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Figure 4.14. Transmission Electron 
Microscopy analysis of AuNPs code A, 
5 nm size (A); AuNPs code B, 30 nm 
size (B); AuNPs code C, 15 nm size (C); 
AgNPs code D, 30 nm size (D); AgNPs 
code E, 20 nm size (E); swCNTs NPs 
code F, 274,6 nm x 1,70 µm (F); SiO2 
NPs code G, 20 nm (G);  SiO2 NPs code 
H, 75 nm (H); ZnO NPs code I, 240 nm 
(I) (nominal size diameter). 
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The TEM images show that all the particles except the swCNT and ZnO can be considered 
approximately spherical and as such are generally suitable for use with the DLS and CLS 
analysis methods. When the swCNT and ZnO results are excluded, the TEM and CLS size 
measurements all show a good general correspondence confirming that these materials are 
present in the stock solutions primarily as single particles. A comparison of these results with 
the DLS derived size measurements shows that DLS derived sizes are generally higher than 
expected from TEM and CLS, but this is common in DLS measurements where results are 
strongly biased in the presence of a small fraction of large particles or aggregates and also 
because DLS measures a hydrodynamic diameter that is expected to be larger than what is 
seen in TEM pictures. This effect derives from the fact that the intensity of the scattered light 
is inversely proportional to the sixth power of the radius of the nanoparticle. As a result, a 
small fraction of large particles may completely mask a large fraction of smaller particles. DLS 
does not distinguish between constituent particles and aggregates/agglomerates. It simply 
gives information about all diffusing ensembles, regardless of whether they are individual 
particles, agglomerates or aggregates. Consequently, DLS analysis of a polydispersed mixture 
will produce results which tend to reflect the size of the largest particles present in a solution 
even when these numerically constitute only a minor fraction of the total population.  
 
4.8 Characterisation of NPs particle size distributions in culture 
medium 
In the previous sections the nanoparticle size distribution of the stock materials have been 
described as they are present in the simple dispersion or original synthesis media and without 
the presence of the proteins and salts which are vital components of the full cell culture 
media used in the validation test protocol. Under these conditions the particles are expected 
to either be fully dispersed (mainly single particles) as in the case of the in-house materials or, 
in the case of suspensions derived from dried powders, be a mixture of single particles and 
mechanically stable aggregates. The majority of particles in this study are likely to maintain 
their colloidal stability via electrostatic stabilisation which generally becomes less effective in 
the presence of dissolved ionic salts. At the salt concentration levels in cell culture media 
there is a high probability that a rapid and irreversible aggregation of normally stable 
nanoparticles will occur. The presence of proteins may mitigate or exasperate the effect of 
salt depending on the nature of the particles and the proteins involved. Consequently, it is not 
generally possible to reliably predict how any single type of particle will behave in any 
particular type of cell culture media and so it is generally advisable to determine this 
behaviour experimentally. In this study the colloidal stability of the test particles when 
exposed to the cell culture media with 10% v/v of serum has been qualitatively evaluated by 
using CLS. A comparison was made between the particles in the as-supplied state, 
immediately after dilution in water or serum-media mixture and then finally after being held 
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for 72 h under standard cell culture conditions (5% CO2, 95% humidity and 37°C). These 
results are reported numerically in Table 4.5. 
 
Table 4.5.   NPs diluted in water or in culture medium with 10% v/v of serum at time 0 and 
after 72 h of incubation. Mean size distribution was measured by CLS. 
 
1
Half Height Width (HHW) 
2
DLS Polydispersivity Index 
nd: not determined 
The results of the CLS analysis of the eight particle types show significant evidence of 
aggregation/agglomeration only in the case of the ZnO and SiO2 particles with the other 
materials retaining a large portion of particulates in the free un-agglomerated state. With the 
exception of the smallest gold nanoparticles a comparison between the CLS size distribution 
in water and in medium with 10% serum show a shift towards an apparently lower size. This 
effect is not necessarily due to any true change in particle size but is an instrumental artefact 
derived from the interactions between the serum proteins and the metallic nanoparticles. 
When citrate stabilized gold and silver nanoparticles are mixed with serum containing culture 
medium, the serum proteins rapidly form a protein corona surrounding the particle which 
stabilised them against aggregation but, at the same time, changes (reduces) the mean 
density of the NPs system. Since the calculation of particle size by the CLS method depends on 
knowing the density of the particle, any change in the actual mean density with respect to the 
theoretical values used by the instrument software will produce a result which will deviate 
proportionately from the expected physical value. In the case of gold particles with a size of 
around 30 nm the formation of the protein corona will produce a slight proportional increase 
in the Stoke’s diameter of the particles but at the same time will decrease the mean density. 
NPs code NPs conc. 
(µM) 
Mean size in water 
(nm/HHW
1
/PdI
2
) 
Mean size in culture medium with 10% 
serum (nm/HHW
1
/PdI
2
) 
 Incubation time 
0 h 0 h 72 h 
A 
200 - 5.1/2.5/2.0 7.9/5.5/1.7 
400 3.3/0.9/1.8 4.3/2.6/2.1 9.3/6.1/1.6 
B 
100 - 20.4/5.9/1.2 21.0/5.6/1.2 
200 - 20.4/6.3/1.2 21.4/5.9/1.1 
400 30.3/5.8/1.1 20.7/8.3/1.2 22.0/6.6/1.2 
C 100 12/1.5/1.4 9.7/nd/2.3 10.2/nd/2.4 
E 10 26.9/5.8/1.2 19.7/9.2/1.5 20.4/6.4/1.4 
F 100 12/1.5/1.4 12.2/0.3/1.2 10.8/0.4/2.3 
G 300 21/6.8/1.30 23/44.2/1.9 136.4/103.6/2.24 
H 1000 71.4/6.5/1.30 64.2/7.9/2.75 160/105/1.52 
I 1280 186.8/144.0/9.9 166.7/124.6/3.2 207.7/195.3/3.4 
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The overall effect on the CLS derived size is to produce a measured value which is apparent 
slightly lower than would normally be expected from the measurements of protein free 
particles. For the small gold particles the absorption of serum proteins, although reducing 
mean particles density, produce an increase in Stoke's diameter which is proportionally much 
more significant than in the case of the 30 nm particles. In this case the net effect of the 
greater diameter and lower density makes the particles appear larger in serum compared to 
particles in protein-free solution. Similar arguments are applicable to the silver nanoparticles.  
The correct size of the NPs-protein complex can be determined by CLS only if the mean 
density of the complex is accurately known and although procedures exist to do this, they are 
experimentally very complex and beyond the requirements of this particular study. However, 
the change in hydrodynamic radius and the decreases in density have an opposite effect it is 
difficult to predict the CLS trend in serum for each particle’s size.  
In this study, CLS has been used for the characterisation of particles exposed to media 
principally to evaluate the extent of any particle aggregation rather than to give precise 
measurement of particle size in the cell culture media. In this respect the method has been 
able to show clearly that when mixed with serum containing media the Au and Ag particles 
remain largely monodispersed with only moderate aggregation/agglomeration while the ZnO 
and silica based materials both show evidence of some degree of aggregation during the 72 h 
period of incubation.  
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5. Approach used for the statistical analysis of data  
obtained from the CFE assay  
 
5.1 Experimental design 
In each experiment (run), a positive control (100 µM sodium chromate, Na2CrO4), a negative 
(untreated) control, a solvent control and three to eight concentrations of the NP were tested 
using the CFE assay. For each run, six dishes per treatment condition were used. The colonies 
of the MDCK cells were counted manually at the end of the experiment. The raw data hence 
consist of the number of colonies counted in each dish for each treatment condition and for 
the controls. The raw data was captured in Microsoft®Excel™ templates, illustrated in Figure 
5.1. 
 
 
Figure 5.1.  Template showing an example of raw data: the number of colonies per 
treatment condition and controls. 
 
The statistical analysis and curve fitting was executed using the software IDBS XLfit™. This 
software completely integrates with Microsoft® Excel™. The complete integration means that 
no script files with the raw data need to be inserted into IDBS XLfit™. 
 
 
 
 
RAW DATA
NP I
Treatment Concentration dish 1 dish 2 dish 3 dish 4 dish 5 dish 6
Positive Control 100µM 0 0 0 0 0 0
Control 0 122 132 120 134 123 154
Solvent Control 0.04% 152 139 132 118 148 142
I 1 145 134 144 149 138 129
I 5 137 133 143 155 141 135
I 10 129 124 135 138 146 143
I 12.5 146 113 131 138 130 145
I 15 72 75 75 82 96 101
I 20 55 28 17 77 41 10
I 25 0 0 0 0 0 0
Number of colonies 
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Figure 5.2.  The statistical analysis and curve fitting are executed using the software IDBS 
XLfit™. 
In the experimental phase, there are three test acceptance criteria. These criteria have to be 
fulfilled for a run to be accepted. The criteria are: 
1. Colonies counted contain more than 50 cells.   
2. The plating efficiency (PE) is higher than 45%. The PE is calculated as the average 
number of colonies in the negative control divided by the number of cells seeded per 
dish.   
3. The positive control shows complete cell death (i.e. no colonies).  
 
5.2 Control data 
As introduced in the experimental design, there are three types of control data in one run: 
1. The positive control (sodium chromate (Na2CrO4) tested at the concentration 100 µM), 
which shows complete cell death. 
2. The negative (untreated) control. 
3. The solvent control, which is NP specific. 
The distribution of the average number of colonies in negative control for each laboratory is 
illustrated by boxplots in Figure 5.3. A red straight line (90 colonies) represents the 
acceptance criterion (2), PE 45% = 90/200 cells seeded per dish. This criterion was not 
completely fulfilled in a couple of runs, as shown in the figure. The total average over all 
Overall mean 129,5 
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laboratories is 129.5 colonies (illustrated as the black dotted line) with a standard deviation of 
24.9. These figures are very similar to the solvent control data, with a total average of 130.3 
colonies with a standard deviation of 25.5. 
  
Figure 5.3.  The distribution of the average number of colonies in negative control per 
laboratory. 
The histograms in Figures 5.4 show the distributions of average number of colonies in 
negative and in solvent control data over all laboratories. Red straight lines (90 colonies) 
represent the acceptance criterion (2). Both distributions are comparable: symmetric and 
reasonably unimodal.  
 
 
Figure 5.4.  Distributions of the average number of colonies in controls. 
 
By looking at the scatter plots in Figure 5.5, we may conclude that the different solvents used 
for the NPs (NPs A-I) do not have toxic effects. The linear relationships are strong between the 
negative and solvent control data, the Pearson product-moment correlation coefficients are 
very high between 0.84 and 0.93.  
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Figure 5.5.  Scatter plots of average negative controls versus average solvent controls. 
 
5.3 Run independency 
For the comparison study, three independent runs are required. Independent runs are 
prepared on different days and/or with different passage numbers of the cell line. Thus, some 
laboratories were omitted from the intra and interlaboratory comparison study because the 
runs were not considered as independent. Some laboratories performed their runs during the 
same days with same cell passage number. In the following figures, laboratories which have 
provided less than three independent runs are marked with an asterisk ‘*’. 
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5.4 Concentration response curve 
The chosen model for the concentration response curve is a four parameter logistic function 
(inhibition, y, versus concentration, x), also called the Hill function: 
   
  
1  	/
 
where the parameters A (minimum of y), B (maximum of y), C (IC50) and D (slope factor) are 
estimated using a Levenberg-Marquardt (L-M) algorithm, see Figure 5.6. 
The L-M algorithm is an iterative numeric minimization algorithm for non-linear squares 
fitting with the measurements regarded as mutually independent of constant variance. The L-
M algorithm interpolates between the Gauss–Newton algorithm and the method of gradient 
descent. We will fit concentration response models to both normalised and raw data (in the 
report only normalised data will be presented). When we are analysing normalised data, we 
are both normalising the raw data against an average negative control and an average solvent 
control value and our curves are constrained to go from 100 down to 0 percent. The main 
inhibitory concentration (ICxx) parameter of interest is the IC50 (the concentration of an 
inhibitor where the response is reduced by half). The overall performance of the inhibitor is 
also interesting, so the IC10 (the concentration of an inhibitor where the response is reduced 
by 10%) and the IC90 for normalised data are also calculated. These parameters are illustrated 
also in Figure 5.6. 
 
 
 
Figure 5.6.  Three inhibitory concentration parameters (IC50, IC10, IC90) are represented in 
the normalized concentration response curve. 
 
The slope factor (Hill slope) quantifies the steepness in the concentration response curve. In 
the standard curve, the slope factor is 1. A steeper curve has a higher slope factor (and a 
more gradual curve has thus a lower slope factor). In this report, only the results of the IC50 
are compared. 
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5.5 Comparison of results, intra and interlaboratory variation 
To be able to evaluate the reproducibility and repeatability of the CFE assay, the intra (within 
laboratory) and interlaboratory (between laboratories) variations are assessed. There are two 
layers of variation within laboratories: between the six dishes within a run and between the 
three runs within one laboratory. The interlaboratory variation is between the 12 
laboratories.  
The different types of variation are illustrated in Figures 5.7 – 5.9: 
4. Intralaboratory, variation within a run, Figure 5.7. 
To analyse the variation within a run, a concentration response model to the 
normalized data for each dish is fitted. Six concentration response models are thus 
fitted, since there are six dishes in one run. 
5. Intralaboratory, variation between runs, Figure 5.8. 
For each run, concentration response curves for normalized (to negative and solvent 
control) data, averaged over the six dishes are generated. This averaged normalized 
curve is one out of the three curves used to calculate the intralaboratory variation 
between runs.   
6. Interlaboratory, variation between laboratories, Figure 5.9. 
The averaged result (of the three runs) from one laboratory is compared with the 
corresponding results from the participating laboratories in the study. 
To assess the protocol transferability of the assay, the variations 1) - 3) are calculated for the 
positive control, sodium chromate (Na2CrO4). For the nine NPs, the variations 2) - 3) are 
assessed to evaluate the reproducibility and repeatability of the assay. 
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Figure 5.7.  An example of intralaboratory variation within a run (6 dishes) 
 
 
Figure 5.8.  An example of intralaboratory, variation between runs (3 runs) 
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Figure 5.9.  An example of interlaboratory variation between laboratories (12 labs). 
 
For the comparison of results, the coefficient of variation (CV) is used as a normalized 
measure of dispersion. The CV expresses the sample standard deviation in terms of the 
sample mean. Consequently, the CV provides a unitless measure of dispersion and a good 
measure for comparison. CVs are used as measures of intra and interlaboratory 
reproducibility. CVs less than 30% are often considered to be of “high quality” in that these 
would be judged to have a small or reasonable level of intra and interlaboratory variability 
(Busquet et al., 2014).
 
 
 
5.6 Deviating observations 
Outliers may be due to variability in the measurement or may indicate experimental errors. 
There is no stringent mathematical definition of what defines an outlier. So determining 
whether an observation is an outlier depends on the question and method used. There are 
numerous model-based methods for outlier identification when data are assumed to come 
from parametric distributions (especially the normal distribution). In this study, one common 
non model-based outlier definition is applied. Observations which are lower than the lower 
quartile (Q1)-3*interquartile range (Q3 - Q1) or higher than the upper quartile 
(Q3)+3*interquartile range (Q3 - Q1) are considered to be outliers and these observations are 
highlighted. No deletion of outlier data are made unless the observations are clearly 
erroneous due to experimental errors. If a data point is excluded from the analysis, it is 
reported. 
An example of an observed outlier, which was excluded from the analysis, may be found in 
run 4 from laboratory 5 (at concentration 1 µM) testing the PC sodium chromate, illustrated 
in Figure 5.10. The set of observations coming from the six dishes are [102   105   102    92    
89    36]. The lower quartile is 89, the upper quartile is 102 and the interquartile range is thus 
102-89=13. Outliers are observations, which are lower than 89-3*13=50 or higher than 
102+3*13=141. Figure 5.10 shows a box plot of the data set, the box has lines at the lower 
quartile (value 89), median (97), and upper quartile values (102). Whiskers extend from each 
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end of the box to the adjacent values in the data and the outlier (36) is displayed with a red 
plus (+) sign. 
 
Figure 5.10.  Boxplot of the number of colonies at concentration 1 µM testing the PC sodium 
chromate, laboratory 5. The outlier is displayed with a red plus (+) sign. 
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6. Results of the interlaboratory comparison study 
6.1 Na2CrO4 positive control  
In each run, seven concentrations of the positive control sodium chromate are tested. 11 
laboratories have provided at least three independent runs but lab 9 has provided two. Three 
independent runs have been randomly selected for laboratories which have provided more 
than three accepted runs. A typical concentration response curve (normalised to the negative 
control) for sodium chromate is shown in Figure 6.1.  
 
 
 
 
 
 
 
 
Figure 6.1.  A typical concentration response curve for sodium chromate from laboratory 5, 
run 2.  
 
6.1.1 Intralaboratory variation within runs 
The bar charts in Figure 6.2 depict the IC50 values from the three runs from the 12 
laboratories. The error bar represents the standard deviation of the six dishes in a run. The 
corresponding scatter plot of intralaboratory CV of IC50 within runs is shown below the bar 
chart. Laboratories 1 and 12 have little variation within runs and hence low CVs. The 
laboratories 4 and 8 tend to have lower IC50 values compared to the other laboratories. 
Laboratory 8 has furthermore considerable variation within the runs, thus large CVs. 
Laboratory 9’s last two runs have similar concentration response curves since they have the 
same experimental conditions and are not independent (laboratory 9’s first run is differing 
substantially). The CVs are in the range from 1.1 to 15.5%. 
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Figure 6.2.  The bar charts depict the IC50 values from the three runs from the 12 labs. The 
error bar represents the standard deviation of the six dishes in a run. The 
corresponding intralaboratory CVs of IC50 within runs is shown in the scatter 
plot (below). Laboratory 9 is marked with an asterisk ‘*’ because it has 
provided less than three independent runs. 
6.1.2 Intralaboratory variation between runs 
Figure 6.3 illustrates the bar charts of the average IC50 values from the three runs with the 
corresponding scatter plot of intralaboratory CV of IC50 between runs (blue dots). 
Laboratories 1, 3, 5, 6, 7 and 12 have similar IC50 values, around 1.5 µM. Moreover, laboratory 
1 has the lowest variation between runs, with a CV of 1.8% (illustrated in Figure 6.3). 
Laboratories 9 and 10 have substantial variation between runs, with CVs of 28.3 and 19.4%, 
respectively. In the case of laboratory 9, the last two runs are not independent (as already 
described in the previous sections) and the first run from laboratory 10 has a lower IC50 value 
than the other two more similar runs. The CVs are in the range from 1.8 to 19.4% (28.3% if the 
non-independent result is included). 
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Figure 6.3.  The bar charts depict the average IC50 values from the three runs from the 12 
laboratories. The error bar represents the standard deviation of the three runs. 
The corresponding intralaboratory CV% of IC50 between runs is shown in the 
scatter plot (below). Laboratory 9 is marked with an asterisk ‘*’ because it has 
provided less than three independent runs. 
 
6.1.3 Interlaboratory variation 
The overall average of the 12 laboratories is 1.22 µM with a standard deviation of 0.27 µM. 
When the results from laboratory 9 are omitted to only have independent results, the overall 
average is 1.24 µM with a standard deviation of 0.28 µM. The interlaboratory CV is 22.5%. 
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6.2 Au NPs code A-B-C 
The gold NPs code A - C differ in size. NP A has the nominal size of 5 nm, NP B 35 nm and NP C 
15 nm. Most laboratories show no response (no toxicity) in the concentration response 
experiments. The typical concentration response curves for NPs A-C are illustrated in Figure 
6.4. 
 
Figure 6.4. Typical concentration response curves with no toxicity for NPs A-C. 
 
NP code A. The response “no toxicity” is found in 10 laboratories, all of which have provided 
three independent runs. Laboratories 8 and 10 are the exceptions; they have provided less 
independent runs and the concentration response curves exhibit toxicity. Laboratory 8 has 
one independent run (the three runs may be seen as one run with 18 replicate dishes because 
the runs were done during the same days with the same cell passage number) and laboratory 
10 has two independent runs. The runs from laboratory 8 have responses at the highest 
tested concentration. The runs from laboratory 10 show a clear concentration response 
relationship. Examples of the concentration response curves from these laboratories are 
shown in Figure 6.5. 
 
 
Figure 6.5.  Concentration response curves for laboratories 8 and 10 for NP code A, marked 
with an asterisk, ‘*’ because they have provided less than three independent 
runs. 
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NP code B. The response “no toxicity” is found in 9 laboratories, which have provided three 
independent runs. Laboratory 8 did not provide any results and laboratory 9 provided results 
from two independent runs. The runs from laboratory 10 exhibit concentration responses as 
illustrated in Figure 6.6. 
 
Figure 6.6.  Concentration response curve for laboratory 10 for NP code B. 
 
NP code C. No toxicity is detected for seven of eight laboratories, which have provided three 
independent runs. Thus four laboratories have provided less than the agreed number of 
independent runs; laboratory 8 did not provide any results, laboratories 9 and 10 have 
provided two independent runs and laboratory 6 has only provided results from one run 
because of a (bacterial) contamination problem. 
Laboratory 11’s runs exhibit toxicity; two runs have responses only at the highest tested 
concentration and one run has a clear concentration response relationship. Laboratory 10’s 
runs also show concentration response relationships. Examples of the concentration response 
curves from laboratories 10 and 11 are shown in Figure 6.7. 
 
 
Figure 6.7.  Concentration response curves for laboratories 10 and 11 for NP code C. 
Laboratory 10 is marked with an ‘*’ because it provided less than three 
independent runs. 
  
45 
 
6.3 Ag NPs code D-E 
The silver NP code D has a nominal size of 30 nm and NP code E a nominal size of 20 nm. All 
laboratories produced concentration responses. Standard concentration response curves for 
NPs D and E are illustrated in Figure 6.8. 
 
 
Figure 6.8.  Typical concentration response curves for NPs D and E. 
 
NP code D. The bar charts in Figure 6.9 depict the average IC50 values from three runs. The 
blue bars represent data normalised to negative controls and red bars normalised to solvent 
controls. The error bar represents the standard deviation of the three runs. Three laboratories 
which have provided less than three independent runs are marked with an asterisk, ‘*’. 
Laboratory 9 provided results from two independent runs. Laboratories 8 and 10 provided 
results from one independent run each. Laboratories 2 and 5 did not provide solvent control 
data for one run each and the related bars are marked with stripes. Laboratories 4 and 12 
have considerable variation between the runs. Laboratory 8 has remarkably low IC50 values.  
For the comparison, the accepted results for 9 laboratories the nine accepted laboratories for 
negative control normalised data and 7 laboratories for solvent control normalised data are 
considered. The intralaboratory CVs are in a majority of cases low and under 20% (six out of 
nine laboratories for negative control normalised data and five out of seven laboratories for 
solvent control normalised data). Laboratories 2, 4 and 12 have high intralaboratory CVs, in 
the range from 43-69%.  
The interlaboratory CVs are low and under 30%, 25.4% in the case when the data are 
normalised to the negative controls and 18.4%  when the data are normalised to solvent 
controls. 
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Figure 6.9.  The bar charts depict the average IC50 values from three runs. The blue bars 
represent normalised negative control data and red bars normalised solvent 
control data. The error bar represents the standard deviation of the three runs. 
Laboratories with less than three independent runs are marked with an 
asterisk ‘*’. Striped bars contain results from two runs. 
 
NP code E. Figure 6.10 illustrates the corresponding bar charts of the average IC50 values from 
NP E. The results for NPs D and E are very similar; the size of the silver NP does not seem to 
have an impact on its toxicity. Nine laboratories have provided results from three 
independent runs. Laboratories 9 and 10 have provided results from two independent runs 
and laboratory 8 from one independent run. Laboratory 11 has substantial variation between 
the runs. Again laboratory 8 has remarkably low IC50 values.  
The intralaboratory CV is low for seven out of the nine accepted laboratories. In these cases 
the CV is below 20% for both types of normalisations (to negative and solvent controls). 
Laboratories 11 and 12 have higher intralaboratory CVs, in the range from 34-58%. 
The interlaboratory CVs are low also for NP E: 25.7% in the case when the data are normalised 
to the negative controls and 24.6% when the data are normalised to solvent controls.  
 
 
NP D
Norm.   
Neg Cont
Norm. 
Solv Cont
# Labs 9 7
Mean IC50 4.0 4.2
Std 1.0 0.8
CV % 25.4% 18.4%
with 3 independent runs
Results from laboratories
NP D – Average IC50 (µM) 
Mean IC50 norm. control Mean IC50 norm. solvent control 
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Figure 6.10.  The bar charts depict the average IC50 values from the three runs. The blue 
bars represent data normalised to negative controls and red bars data 
normalised to solvent controls. The error bar represents the standard deviation 
of the three runs. Laboratories with less than three independent runs are 
marked with an asterisk ‘*’. 
 
6.4 swCNTs code F 
For the swCNT, nine laboratories observed no toxicity in three independent runs. As for NPs 
D-E laboratories 8, 9 and 10 provided less than three independent runs. Laboratories 9 and 10 
provided results from two independent runs and laboratory 8 from one independent run. 
Furthermore, laboratory 9’s runs established concentration response relationships (responses 
were already detected at the lowest tested concentration, Figure 6.11). This response was not 
observed for laboratories 8 and 10. 
NP E
Norm.   
Neg Cont
Norm.   
Solv Cont
# Labs 9 9
Mean IC50 3.9 4.0
Std 1.0 1.0
CV % 25.7% 24.6%
with 3 independent runs
Results from laboratories
NP E – Average IC50 (µM) 
Mean IC50 norm. control Mean IC50 norm. solvent control 
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Figure 6.11.  Typical concentration response curve with no toxicity (to the left)                                             
and a curve with a concentration response for laboratory 9 (to the right) which 
provided two independent runs, thus marked with an asterisk ‘*’. 
 
6.5  SiO2 NPs code G-H 
NPs code G-H are silicon dioxide (SiO2) NPs with the nominal sizes of 20 nm and of 90 nm, 
respectively. As for the previous NPs, nine laboratories have tested three independent runs. 
The exceptions are laboratories 9, 10 (two independent runs) and laboratory 8 (one 
independent run).  
NP code G. For NP G, no concentration response relationship was observed in any of the 
laboratories. 
NP code H. Most laboratories show no response to the tested NP code H, but at the highest 
tested concentration the following laboratories observed same toxicity: two runs from 
laboratory 4 and one run from laboratory 12. In addition, the three non-independent runs 
from laboratory 8 and one run from laboratory 9 show responses at the highest tested 
concentration. Figure 6.12 illustrates the standard curve for NP G and H and two examples of 
curves with responses. 
 
 
Figure 6.12. Typical curve with no toxicity for most laboratories and curves with concentration 
responses for NP H for laboratories 4 and 8. Laboratory 8 marked with an 
asterisk, ‘*’ because it provided one independent run. 
 
 
  
49 
 
6.6  ZnO NPs code I 
The coded NP I is a zinc oxide (ZnO) NP with the nominal size of 240 nm. As for the previous 
NPs, nine laboratories have tested three independent runs. Laboratories 9 and 10 have 
provided results from two independent runs and laboratory 8 has provided results from one 
independent run. All laboratories generated concentration responses. The average IC50 values 
from NP I are depicted in Figure 6.13. For the nine accepted laboratories the intralaboratory 
CVs are in general low. In eight cases they are around or below 20% for both types of 
normalisations. The exception is laboratory 5, where the CVs are just on the 30% limit for 
both types of normalisations. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13. The bar charts depict the average IC50 values from the three runs. The blue bars 
represent data normalised to negative controls and red bars data normalised to 
solvent controls. The error bar represents the standard deviation of the three 
runs. Laboratories with less than three independent runs are marked with an 
asterisk ‘*’. 
NP I
Norm.   Neg 
Cont
Norm.   Solv 
Cont
# Labs 9 9
Mean IC50 17.6 17.9
Std 6.4 6.8
CV % 36.5% 37.8%
Results from laboratories
with 3 independent runs
NP I – Average IC50 (µM) 
Mean IC50 norm. control Mean IC50 norm. solvent control 
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The interlaboratory CVs are somewhat higher than for NPs D and E; 36.5% when the data are 
normalised to the negative controls and 37.8% when the data are normalised to solvent 
controls, see Figure 6.13. These high figures are partly due to the deviating results from 
laboratory 3, see Figure 6.14.  
 
 
Figure 6.14.  Typical concentration response curve for NP I (to the left) and curve for 
laboratory 3 (to the right).  
 
6.7 Deviations from the Standard Operating Procedure  
Deviations from the Standard Operating Procedure (SOP) were encountered, mainly 
concerning the cells and counting of the colonies. One laboratory incubated the cells for 
longer time than specified in the SOP (one extra day) and one laboratory seeded more cells 
than stated in the SOP (300 cells instead of 200 cells per dish). In some runs from one 
laboratory, two operators counted three dishes each. For consistency all dishes in one run 
should be counted by one operator to avoid an operator bias. 
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7. Conclusions and Recommendations  
 
 
 
 
 
 
 
 
The reliability of the CFE assay for testing of NMs has been assessed through a large 
comparison study with 12 participating laboratories testing nine NPs in at least three 
independent runs.  
First, the protocol transferability of the CFE assay was assessed, by testing the positive control 
chemical sodium chromate (Na2CrO4). The participating laboratories considered that the CFE 
assay protocol, as used in the study is well defined and is easily and reliably transferable to 
other laboratories. This was confirmed by the analysis of the intralaboratory variations (within 
a run as well as between runs) and the interlaboratory variation. The results from the 
participating laboratories show a very good intra and interlaboratory reproducibility and 
repeatability. For all laboratories, the CVs (of IC50) are less than 20% for both types of 
intralaboratory variations and 23% in the case of the interlaboratory variation. CVs less than 
30% are frequently considered to be an indicator of small or reasonable intra and 
interlaboratory variability. 
Secondly, the nine NPs were tested in the CFE assay and the intralaboratory variation 
(between runs) and the interlaboratory variation were assessed. Table 7.1 gives an overview 
of the results for the nine NPs tested for laboratories, which have provided three independent 
runs. All laboratories have obtained concentration responses for NPs D, E and I and no 
responses (no toxicity) for NPs A, G and NM F. For the gold NPs B and C all, except for one 
laboratory, have observed no toxicity. The exceptions are laboratory 10 for NP B and 
laboratory 11 for NP C. For NP H, all laboratories, except for two runs from laboratory 4 and 
one run from laboratory 12, find no toxicity. Only at the highest tested concentration, these 
runs have shown some response.  
For NPs D, E and I, the results obtained confirm good intra and interlaboratory reproducibility 
and repeatability. In most cases, the CVs (of IC50) are less than 20% for the intralaboratory 
variation. In the case of the interlaboratory variation the CVs are less than 30% for NPs D and 
 The CFE assay is a suitable and robust in vitro method to assess cytotoxicity of NMs  
 The assay protocol is well defined and is easily and reliably transferable to other 
laboratories 
 The results obtained show good intra and interlaboratory reproducibility of the assay 
for both the positive control and the tested nanomaterials  
 The assay can be recommended as a building block of an in vitro testing battery, as a 
first choice method to define dose-effect relationships for other in vitro assays 
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E and less than 40% for NP I. Furthermore, the results for NPs D and E are very similar and 
show that in the conditions of the test, the size of the silver NP does not have an impact on its 
toxicity. 
Table 7.1.  Summary of test results. For NP H, the number in the table is marked with the caret 
sign ‘^’ since some results from the accepted laboratories were not congruent. All 
accepted laboratories, except for two runs from laboratory 4 and one run from 
laboratory 12, find no toxicity. Only at the highest tested concentration, these runs 
have shown some response.  
Laboratories with three independent runs 
NP 
code 
NP 
name 
NP nominal 
size (nm) 
Results # 
labs 
Result # concordant 
labs / # labs 
A Au NP 5 10 No toxicity 10/10 
B Au NP 35 10 No toxicity 9/10 
C Au NP 15 8 No toxicity 7/8 
D Ag NP 30 8 Concentration response 9/9 
E Ag NP 20 9 Concentration response 9/9 
F swCNT - 9 No toxicity 9/9 
G SiO2 NP 20 9 No toxicity 9/9 
H SiO2 NP 90 9 No toxicity 8^/9 
I ZnO NP 240 9 Concentration response 9/9 
 
A drawback identified by the laboratories was that the assay is quite laborious and has a 
relatively low throughput. Therefore, in order to fully recommend it as a screening assay, its 
throughput should be increased. Efforts to downscale the assays (e.g. to 6-well or 24-well 
plates) and adapt it for high-content image analysis platforms are already ongoing.  
Based on the result of this interlaboratory study it could be concluded that the CFE assay is a 
suitable method to assess cytotoxicity of NMs and it has several advantages over the 
conventional cytotoxicity assays, as it avoids test interferences. Furthermore, the experience 
gained at the JRC shows that the test is particularly sensitive, as compared to other types of 
cytotoxicity assays (Ponti et al.., 2006). Therefore, it could be included in a testing battery as 
an early screening method. It may well be used in combination with other in vitro assays (e.g. 
genotoxicity in vitro assays, such as micronucleus TG 487) to define the subtoxic doses in 
vitro. It has to be noted that for suspension cells or cells not forming colonies a similarly 
sensitive cytotoxicity assay will need to be defined and validated for NMs testing. 
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APPENDIX 1 Standard Operating Procedure (SOP) for 
culturing MDCK cells 
 
I. INTRODUCTION 
The MDCK cell line was derived from a kidney of an apparently normal adult female cocker 
spaniel, September, 1958, by S.H. Madin and N.B. Darby.II. This line is hyperdiploid and there 
is a bi-modal chromosome number distribution. There are no consistent identifiable marker 
chromosomes. One normal X chromosome is present in most spreads. The cells are positive 
for keratin by immunoperoxidase staining. MDCK cells have been used to study processing of 
beta amyloid precursor protein and sorting of its proteolytic products. Cells form colonies 
when cultured in subconfluent state.  
 
II. PURPOSE 
To maintain MDCK cells in culture for a defined period in order to perform subsequent 
experiments. Cells are maintained in a sub-cultured state (less than 70% confluence) in 
Corning® 75 cm
2
 culture flasks. 
 
III. LIMITATIONS 
MDCK cells have to be passaged at least three times after thawing, before being used in the 
Colony Forming Efficiency assay (passage 1 is the first passage after thawing). A new batch of 
cells from the frozen stock has to be thawed when the old batch in culture reaches passage 
number 6. The Colony Forming Efficiency assay has to be performed using cells in culture at 
maximum passage 10. 
 
IV. METHOD OUTLINE 
MDCK cells are routinely grown as a monolayer in tissue culture grade flasks (Corning® 75 cm
2
 
culture flasks, cat. number 430641, Corning, USA) at 37°C, 95 % humidity, and 5% CO2. The 
cells have to be sub-cultured in a new culture flask when cells are sub-confluent (~70% 
confluence). Stocks of MDCK cells can be stored in sterile cryo vials, in liquid nitrogen. 
Dimethyl sulfoxide (DMSO) is used as a cryo protective agent. The cells under culture 
condition are always cultured at a density of 1x10
5
 cells/75 cm
2
 culture flask. Only cells frozen 
in cryo vials contain 1x10
6
 cells/cryo vial. 
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V. MATERIALS 
Cell culture type 
MDCK cells European Collection of Cell Cultures (ECACC, Sigma catalogue number 84121203, 
Lot. number 06F015) passage 10 were supplied by JRC to each partner. 
 
Technical Equipment and Culture plates 
[Note: Suggested brand names/suppliers are listed in parentheses] 
• Incubator: 37°C, 95 % humidity, and 5% CO2 
• Laminar flow clean bench/cabinet (standard: "biological hazard") 
• Water bath: 37°C  
• Inverse phase contrast microscope 
• Centrifuge  
• Cell counter or haemocytometer (e.g. Bürker Chamber) 
• Pipetting aid  
• Pipettes, pipettors 
• Cryo vials 
• Tissue culture flasks (Corning® 75 cm
2
 culture flasks, Corning, cat. number 430641) 
 
Reagents, Medium and Serum 
• Dulbecco’s Modified Eagle’s Medium 1X (DMEM) [+] 4.5g/L Glucose [+] L-Glutamine, [-
] Pyruvate (Gibco, cat. number 41965 used by JRC, ENEA, ISS, NIOM, NIOH, EMPA, CEA 
and IPL; Gibco, cat. number 11965 used by KRISS, NIER, NIFDS and AIST) (store at +4°C) 
• Fetal Clone II, Bovine serum product, Optimised for CHO cells (Thermo Scientific 
HyClone, cat. number SH30066.03 lot. number AYB58974 used by JRC, CEA, IPL, NIOH 
and NIOM; cat. number SH30066.03 lot. number AUJ35588 used by AIST; cat. number 
SH30066.03 lot. number AWJ22309 used by ENEA (or lot. Number AUE34894), ISS and 
EMPA; Gibco/Invitrogen cat. number 16000 lot. number 1365348 used by KRISS; cat. 
number 16000 lot. number 1221293 used by NIER; cat. number 30067 lot. number 
8190771 used by NIFDS)(store at -20°C) 
• Non-essential amino acids MEM NEAA 100X (Gibco, cat. number 11140) (store at +4°C) 
• Penicillin/streptomycin solution 10000 Unit/mL Pen.; 10000 Unit/mL Strep. (Gibco, 
cat. number 15140) (store at -20°C) 
• Phosphate Buffered Saline (PBS) without Ca
2+
 and Mg
2+
 (Gibco, cat. number 20012) 
(store at Room Temperature) 
• 0.05% Trypsin-EDTA (Ethylenediaminetetraacetic acid)(1X), Phenol red solution (Gibco, 
cat. number 25300) (store at -20°C) 
• Dimethyl sulfoxide (DMSO) ≥99.5%, CAS. 67-68-5 (Sigma-Aldrich, cat. number D5879) 
(store at Room Temperature) 
• Trypan Blue solution 0.4% (Gibco, cat. number 15250) (store at Room Temperature) 
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List of materials that are mandatory to use: 
• Tissue culture flasks (Corning® 75 cm
2
 culture flasks, Corning, cat. number 430641) 
• Dulbecco’s Modified Eagle’s Medium 1X (DMEM) [+] 4.5g/l Glucose [+] L-Glutamine, [-] 
Pyruvate (Gibco, cat. number 41965) 
• Fetal Clone II, Bovine serum product, Optimised for CHO cells (Thermo Scientific 
HyClone, cat. number SH30066.03 lot. number AYB58974 used by JRC, CEA, IPL, NIOH 
and NIOM; cat. number SH30066.03 lot. number AUJ35588 used by AIST; cat. number 
SH30066.03 lot. number AWJ22309 used by ENEA (or lot. Number AUE34894), ISS and 
EMPA; Gibco/Invitrogen cat. number 16000 lot. number 1365348 used by KRISS; cat. 
number 16000 lot. number 1221293 used by NIER; cat. number 30067 lot. number 
8190771 used by NIFDS)(store at -20°C) 
• Non-essential amino acids MEM NEAA 100X (Gibco, cat. number 11140) 
• Penicillin/streptomycin solution 10000 Unit/mL Pen; 10000 Unit/mL Strep (Gibco, cat. 
number 15140) 
Guideline for preparation of aliquot Pen/Strep, Trypsin and Serum 
• Pen/strep: Under sterile conditions prepare 5 mL aliquots in 15 mL Falcon tubes  
• Trypsin: Under sterile conditions prepare 10 mL aliquots in 15 mL Falcon tubes.  
• Serum: 
- Defreeze the serum in a thermostatic bath at 37°C 
- Heat the thermostatic bath to 56°C and put the bottle of the serum inside the 
bath for 30 min. 
- Mark 50 mL Falcon tubes with the name of the serum and the origin (e.g. Fetal 
Clone II U.S. origin), serum batch, catalogue number, date of the aliquots 
preparation  
- After 30 min of incubation remove the bottle from the thermostatic bath and 
prepare, under sterile conditions, aliquots of 50 mL serum in each tube  
- Close the Falcon tubes and wrap the caps with parafilm 
- Store the aliquots at -20°C 
VI. METHODS 
Preparation of Complete Culture Medium and Freezing Medium 
[Note: All solutions, glassware, pipettes, etc. have to be sterile where adequate. All methods 
and procedures will be adequately documented] 
• Complete Culture Medium for routine culture (store at + 4°C) 
Complete cell culture medium is prepared, under sterile conditions as follow: 
- Open a 500 mL Dulbecco’s Modified Eagle’s Medium 1X (DMEM) [+] 4.5g/l 
Glucose  [+] L-Glutamine, [-] Pyruvate (Gibco, cat. number 41965)  
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- Add 50 mL of Fetal Clone II, Bovine serum product, Optimised for CHO cells  
(Thermo Scientific HyClone, cat. number SH30066.03) (10 % v/v)  
- Add 5 mL of Non Essential a.a. MEM NEAA 100X (Gibco, cat. number 11140) (1 
% v/v) 
- Add 5 mL Penicillin/streptomycin solution 10000 Unit/mL Pen.; 10000 Unit/mL 
Strep. (Gibco, cat. number 15140) (1 % v/v) 
Complete cell culture medium should be stored at +4°C for no longer than three 
weeks. 
• Freezing Medium (freshly prepared) 
- 80 % (v/v) complete culture medium 
- 10 % (v/v) serum 
- 10% (v/v) DMSO (Sigma-Aldrich, cat. number D5879) (final conc. in cryovial 5%) 
Cell maintenance and culture procedures 
Routine culture 
MDCK cells are routinely cultured in a sub-confluent state (maximum 70% confluency) in 75 
cm
2
 culture flasks (Corning, cat. number. 430641, USA) at 37°C, 95 % humidity, and 5% CO2. 
The cells have to be examined daily under a phase contrast microscope, and any changes in 
morphology or their adhesive properties noted in a Study Workbook.  
Receipt of cells in culture from the JRC 
The MDCK cells will be shipped in culture flasks completely full of culture medium. Upon 
receipt completely remove the culture medium, wash once with 10 mL of PBS pre/warmed to 
room temperature and add 10 mL of freshly prepared complete cell culture medium pre-
warmed to room temperature, under sterile conditions. Leave cells in the incubator (37°C, 95 
% humidity, and 5% CO2) overnight and the following day, either change the medium or start 
splitting them following “subculture of cells" instructions, if cells are already subconfluent (50-
70% confluence). 
Preparation of the working stock and freezing of the cells 
A working stock of MDCK cells will have to be prepared once cells arrive to each laboratory 
from the JRC. The cells that arrive from the JRC will have passage number 10; the working 
stock will have passage number 11. Cells used right after thawing might show adverse effects 
due to the thawing process, therefore an adaptation time of three passages (passage number 
11 (+1) to passage number 11 (+3)) should be given to the cells before using them in an 
experiment. Additionally, cells should not be used in the Colony Forming Efficiency assay after 
the 10
th
 passage after the start of culturing the cells (passage 11+10). Therefore, to assure a 
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constant supply of cells suitable for experiments, new cells should be thawed, when the 
culture in use is at passage 11 (+6) (Figure S1).  
To prepare the working stock follow the procedure below: 
• Once the cells arrive to the laboratory remove all the culture medium from the flask, 
wash once with 10 mL of PBS pre-warmed to room temperature and add 10 mL of 
freshly prepared complete cell culture medium pre-warmed to room temperature. 
Incubate the cells overnight in the incubator and detach them as described below in 
section "Subculture of cells" the day after 
• After detachment, re-suspend all the cells in 60 mL of complete culture medium 
(without counting them) and distribute into 6 culture flasks (75 cm
2
) by adding 10 mL 
of cell suspension into each flask 
• Cells will reach a subconfluent state (~ 70% confluence) in approximately 3-5 days (if 
not, wait longer until sub-confluence is reached, changing medium twice a week) 
• Once the cells have reached subconfluent state, freeze them as follow: 
- Detach cells from all the 6 culture flasks using trypsin-EDTA and collect them in 
a single 50 mL tube and count as described below in "Cell counting" section  
- Calculate the number of cryo vials to be prepared, considering that each vial 
should contain 1x10
6
 cells. Mark each cryo vial with cell name, passage number 
and date 
- Prepare the freezing medium as described above (0.5 mL for each cryo vial) 
- Centrifuge the cell suspension in a 50 mL tube (200xg, 10 min.) 
- Remove the supernatant leaving the amount of complete medium in which the 
cell pellet will be re-suspended for freezing (e.g. 1 mL for 2 vials). The density 
of this cell suspension should be 2x10
6
 cell/mL (since it will be diluted 1:1 with 
freezing medium to a final number of 1x10
6
 cells in each cryo vial) 
- Open the cryo vials under the biological hood and distribute 0.5 mL of freezing 
medium into each vial and place them on ice 
- Gently re-suspend cells in the culture medium which remained in the 50 mL 
tube, and distribute 0.5 mL of this cells suspension into each cryovial 
- Mix the cell suspension with the freezing medium. This step is extremely 
important in order to avoid the formation of two phases solution during the 
freezing 
- Place the cryo vials in an isolated container (e.g. styrofoam trays) and store at   
-80°C for 24 h 
- After 24 h place the frozen cryo vials into liquid nitrogen (or –150°C freezer) for 
long term storage 
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Figure S1.  Preparation of the MDCK working stock 
 
Thawing of the working stock of cells 
• Remove cryo vials from the liquid nitrogen and thaw cells by putting vials into a water 
bath at 37°C  
• Re-suspend the cells in 9 mL of pre-warmed complete cell culture medium and 
transfer in a 75 cm
2 
culture flasks 
• Incubate at 37°C, 95 % humidity, and 5% CO2 for 24 h 
• After 24 h change culture medium and replace with fresh pre-warmed (37 °C) 
complete cell culture medium and culture as described above 
• After thawing, passage the cells at least three times before using in the CFE assay 
[Note: A fresh batch of frozen cells from the working stock should be thawed out and cultured 
when the working stock in culture reaches passage number 11 (+7). The CFE experiment will 
 
Receive cells with passage 10 
Wash and renew medium (10 mL) 
 
Wait until cells are subconfluent 
Detach cells and suspend in 60 mL complete medium 
 Distribute 10 mL each in 6 flasks and incubate 
No counting is required 
Mark as passage 11 
 
Harvest and freeze cells as described in the SOP to create the working stock 
 
Overnight incubation 
Wait for 50-70% confluence 
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at least after 3 passages of cells in culture 11 (+3) and cells can be used until passage (+10)n as 
described in Figure S2] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2.  Maintenance of MDCK cells in the laboratory. 
 
Subculture of cells 
When cells exceed 50% confluence (but are less than 70% confluent), they have to be split by 
trypsinization, as follow: 
• Warm-up the complete culture medium at 37 °C in the thermostatic water bath for at 
least 15 min 
• Under sterile conditions, wash the cells twice with 10 mL of PBS 
• Add 1 mL trypsin-EDTA solution into each 75 cm
2 
culture flask 
• Place the flask in the incubator for 2-5 min 
• Verify under the microscope that the cells are detached. If necessary, release the cells 
by manually tapping on the sides of the flask until detachment is observed 
• Add 9 mL of complete culture medium and disperse the cells by gentle pipetting 
Thaw one vial of working stock (passage 11) as described in the SOP 
 
Mark as passage 11 (+ 1) and incubate 
 
Start CFE assay at Passage 11 (+3) 
 
Passage 11 (+7) 
 
Passage 11 (+10); Discard batch 
Re-suspend in 9 mL complete medium 
Wait for 50-70% confluence and subculture three 
times until you reach passage 11(+3) 
Continue to use batch for 
3 more passages 
Continue to use batch for 
3 more passages 
Thaw new vial of working 
stock passage 11 and treat as 
above 
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• Count cells as described in section "Cell counting" below 
• Seed 1x10
5 
cells into each 75 cm
2 
culture flask with 10 mL of complete culture 
medium. Cells will reach 50% confluence in approximately 3-4 days 
Cell counting 
It is important to obtain a single cell suspension for exact counting, so gently disperse the cell 
pellet using a 10 mL pipet.   
• Take 30 μL of cell suspension and add 30 μL of 0.4% Trypan Blue solution (Gibco, cat. 
number 15250) in a 2 mL micro-centrifuge tube (dilution factor = 2). Mix the solution 
well by pipetting with 200 μL pipette  
• Count a sample (~10 μL) of the cell suspension using a haemocytometer or cell 
counter (e.g., Bürker Chamber)  
• For a Bürker Chamber the number of cells/mL is calculated using the following 
formula: 
N = {[(a + b)/2]/ 9 x 10
4
x DF}  
where: 
N = number of cells/mL 
a = number of cells counted in 9 squares of the first chamber 
b = number of cells counted in 9 squares of the second chamber 
10
4 
= Conversion factor of the chamber volume 
DF = Dilution factor of the cell suspension (usually equal to 2) 
The appropriate formula has to be applied for other counting devices with taking the 
dilution factor into account. 
• Re-suspend the required number of cells (i.e. 1x10
5
 taken directly from the cell 
suspension) in 10 mL of complete culture medium and culture in a new 75 cm
2
 culture 
flask 
• After detaching the cells into a single cell suspension for subculture, cell viability, 
determined by staining with vital dye Trypan blue, should be higher than 80% 
VII. HEALTH SAFETY AND ENVIRONMENT 
All procedures have to be carried out under aseptic conditions and in the sterile environment 
of a laminar flow cabinet (biological hazard standard). Gloves and laboratory coat must be 
worn by operators. Only sterile equipment must be used in cell handling. Discard all the 
materials used following the appropriate procedure for special biological waste. During 
handling of cryogenic vials in liquid nitrogen, a full-face mask and appropriate gloves must be 
worn.  
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APPENDIX 2 Standard Operating Procedure (SOP) for 
CFE assay 
I. MATERIALS 
Cell Culture type 
MDCK cells, (European Collection of Cell Cultures (ECACC), Lot. number 06F015). Passage 10 is 
supplied by JRC. 
 
Technical Equipment 
• Incubator: 37°C, 95% humidity, 5% CO2 
• Class II biological safety cabinet 
• Water bath: 37°C  
• Inverse phase contrast microscope 
• Stereomicroscope 
• Centrifuge  
• Analytical balance 
• Cell counter or haemocytometer (e.g. Bürker Chamber) 
• Pipetting aid  
• Pipettes, pipettors  
• Vacuum pump 
• Aspirator  
• Tissue culture flasks (Corning® 75 cm
2
 culture flasks, cat. number 430641, Corning,  
USA)  
• Tissue culture dishes (BD Falcon 60x15 mm Style, 20/bag, cat. number 353004, BD      
Falcon , USA) 
• Filter Unit -500 or 1000 mL (Nalgene cat. number 166-0045) or equivalent  
 
Reagents, Medium, Serum  
• Dulbecco’s Modified Eagle’s Medium 1X (DMEM) [+] 4.5g/L Glucose  [+] L-Glutamine, [-
] Pyruvate (Gibco by Life Technologies Cat. number 41965) (store at +4°C) 
• Fetal Clone II, Bovine serum product, Optimised for CHO cells (Thermo Scientific 
HyClone, cat. number SH30066.03 lot. number AYB58974 used by JRC, CEA, IPL, NIOH 
and NIOM; cat. number SH30066.03 lot. number AUJ35588 used by AIST; cat. number 
SH30066.03 lot. number AWJ22309 used by ENEA (or lot. Number AUE34894), ISS and 
EMPA; Gibco/Invitrogen cat. number 16000 lot. number 1365348 used by KRISS; cat. 
number 16000 lot. number 1221293 used by NIER; cat. number 30067 lot. number 
8190771 used by NIFDS)(store at -20°C) 
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• Non-essential a.a. MEM NEAA 100X (Gibco by Life Technologies cat. number 11140) 
(store at +4°C) 
• Penicillin/streptomycin solution 10000 Unit/mL Pen.; 10000 Unit/mL Strep. (Gibco by 
Life Technologies cat. number 15140) (store at -20°C) 
• Phosphate Buffered Saline (PBS) without Ca
2+
 and Mg
2+
 (Gibco by Life Technologies cat. 
number 20012) (store at Room Temperature) 
• Trypsin-EDTA (Ethylenediaminetetraacetic acid) solution (Gibco by Life Technologies 
Cat. number 25300) (store at -20°C)  
• Dimethyl sulfoxide (DMSO), CAS. 67-68-5 (Sigma-Aldrich cat. number D5879) (store at 
Room Temperature) 
• Trypan Blue stain 0.4% (Gibco, cat number 15250 or equivalent) (store at Room 
Temperature)  
• Formaldehyde solution, ACS reagent, 37 (w/v) % in H2O (Sigma-Aldrich cat. number 
25254-9 or equivalent)  
• Giemsa Stain Modified solution (Sigma-Aldrich cat. number GS500-500mL) 
• Sodium Chromate, Na2CrO4 (Sigma Aldrich cat. number 307831; CAS number 7775-11-
3, m.w. 161.97) 
 
List of materials that are mandatory to use: 
• Tissue culture flasks (Corning® 75 cm
2
 culture flasks, Corning, cat. number 430641) 
• Tissue culture dishes (BD Falcon 60x15 mm Style, 20/bag, cat. number 353004, BD      
Falcon , USA) 
• Dulbecco’s Modified Eagle’s Medium 1X (DMEM) [+] 4.5g/L Glucose [+] L-Glutamine, [-
] Pyruvate (Gibco, cat. number 41965) 
•   Fetal Clone II, Bovine serum product, optimized for CHO cells (Thermo Scientific 
HyClone, cat. number SH30066.03) 
•   Non-essential amino acids MEM NEAA 100X (Gibco, cat. number 11140) 
• Penicillin/streptomycin solution 10000 Unit/mL Pen.; 10000 Unit/mL Strep. (Gibco, cat. 
number 15140) 
 
II. IDENTIFICATION OF CONTROL SUBSTANCES 
• Positive control: Sodium Chromate, Na2CrO4 (Sigma Aldrich cat. number 307831; CAS 
Number 7775-11-3, m.w. 161.97), 100 µM 
• Solvent Control: Complete cell culture medium with the addition of the solvent that is 
used for synthesis and suspension of nanomaterials. The concentration (v/v) of solvent 
in the Solvent Control medium corresponds to that present in the highest tested 
concentration of nanomaterial and is the same in each NMs concentration tested. 
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III. METHODS 
[Note: All solutions, glassware, pipettes, etc. have to be sterile and all procedures have to be 
carried out under aseptic conditions and in the sterile environment of a class II biological 
safety cabinet until when cells are ready for fixation and staining. All methods and procedures 
will be adequately documented] 
 
Method outline: 
Day 1 Cell seeding 
Day 2 Exposure to nanoparticles 
Day 5 End of exposure (72 h), change of medium 
Day 8 Fixation and Staining 
Day 9 Counting of the colonies and data elaboration 
 
Day 1. Cell seeding  
Preparation of cells for seeding 
When cells cultured in 75 cm
2 
flasks exceed 50 % confluence, but are less than 70% 
confluence, they are ready to be used for CFE assay.  
Detach cells from the 75 cm
2 
culture flasks as follow: 
• Warm up the complete cell culture medium at 37°C in the thermostatic water bath for 
at least 15 min 
• Under sterile conditions, wash the cells in 75 cm
2 
culture flask twice using 10 mL of PBS 
• Add 1 mL trypsin-EDTA solution into each 75 cm
2 
culture flask 
• Place the flasks in the incubator for 2-5 min 
• Verify under the microscope if cells are detached. If necessary, release the cells by 
manually tapping on the sides of the flask until when complete detachment is 
observed 
• Add 9 mL of complete culture medium and disperse the cells by gentle pipetting. Since 
it is important to obtain a single cell suspension for exact counting, gently disperse the 
cell pellet using a 10 mL pipette 
 
Cell counting 
• Take 30 μL of cell suspension and add 30 μL of 0.4% Trypan Blue solution (Gibco, cat 
number 15250) in a 2 ml microcentrifuge tube (dilution factor = 2). Mix the solution 
well by pipetting with 200 μL pipette 
• Count a sample (~10 μL) of the cell suspension using a haemocytometer or cell 
counter (e.g., Bürker Chamber)  
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• For a Bürker Chamber the number of cells/mL is calculated using the following 
formula: 
 
N = {[(a + b)/2]/ 9 x 10
4
 x DF}  
where: 
N = number of cells/mL 
a = number of cells counted in 9 squares of the first chamber 
b = number of cells counted in 9 squares of the second chamber 
10
4 
= Conversion factor of the chamber volume 
DF = Dilution factor of the cell suspension (usually equal to 2) 
 
After detaching the cells into a single cell suspension for subculture, cell viability determined 
by staining with vital dye Trypan blue, should be higher than 80%. 
 
Calculation of the number of cells to be seeded for CFE assay and volume in which cells are 
suspended 
• Each BD Falcon 60x15 mm dish must contain 200 cells suspended in 3 mL of complete 
culture medium. For each test concentration (NPs test suspensions) and control, 6 
dishes are seeded (6 replicates) 
• Calculate the total number of dishes used for the experiment:  
Example: 
- 3 test concentrations + 1 positive control + 1 negative control + 1 solvent control 
correspond to 6 treatment conditions in total  x 6 replicates = 36 dishes in total 
- Calculate at least 4 dishes more than needed (36 + 4 = 40) 
- Multiply 200 cells/dish x 40 dishes = 8000 cells 
- Multiply 40 dishes x 3 mL of culture medium = 120 mL 
 
Preparation of the 60x15 mm dishes 
• Open the dishes bags under the class II biological safety cabinet biological hood, under 
sterile conditions 
• Write on each dish the name and concentration of the NPs to which the cells will be 
exposed; indicate C for control; C+ for positive control; C solv. for solvent control 
 
 Cell seeding  
• Prepare the seeding cell suspension that contains the number of cells needed for 
seeding (e.g. 8000 cells) in the necessary volume (e.g. 120 mL), as previously calculated 
• Volume of ‘initial’ cell suspension (X) needed to prepare the ‘seeding’ cell suspension is 
calculated using the following formula:   X = M / N 
Where: 
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- N = number of cells/mL in the ‘initial’ cell suspension obtained after 
detachment of cells from 75 cm
2
 flasks 
- M = number of cells needed for cell seeding in all BD Falcon 60x15 mm dishes 
(e.g. 8000 cells as in our example presented above)   
• Add into a sterile bottle the calculated volume of complete culture medium needed to 
fill all dishes (e.g. 120 mL as in our example presented above) 
• Remove X mL of medium from the bottle and add X mL of the ‘initial’ cell suspension. 
• Gently mix the obtained cell suspension using a 10 mL pipette 
• Aspirate 9 mL of cell suspension using a 10 mL pipette 
• Fill 3 BD Falcon 60x15 mm dishes with 3 mL suspension each (9 mL in total) 
• Put the dishes in the incubator  
• Repeat the procedure until when all the dishes have been filled. It is important to mix 
(aspirating at least 3 times) the cell suspension before taking the new 9 mL aliquot of 
cells for seeding 
• Leave the cell cultures in the incubator for 24 h 
To have an accurate and reproducible cell seeding in all dishes, it is extremely important to be 
precise in all the steps described above. 
Day 2: Exposure to nanoparticles and controls 
• Twenty four hours after cell seeding, on Day 2, proceed to the exposure of the cells to 
the tested compounds/nanoparticles 
• Prepare the suspensions of nanoparticles and the dilutions of solvent and positive 
controls 
• For each treatment condition, remove an adequate amount of volume from the dish 
• Add directly to the medium in the dish the adequate volume of previously prepared 
suspension of nanoparticles, or solution of solvent or positive controls. Nothing is 
added to the medium in the negative control dishes 
• Assure a homogenous distribution by swirling the dish slightly in a circular way 
Day 5: End of exposure (72 h) 
• Remove the exposure medium from the dishes (3 mL/dish) 
• Add 3 mL/dish of fresh complete cell culture medium 
Day 8: Fixation and staining 
• Prepare the fixing solution in PBS by adding 10% (v/v) of the Formaldehyde solution 
(ACS reagent, 37 (w/v) % in H2O) 
e.g. 50 mL Formaldehyde solution + 450 mL PBS 
• Prepare the staining solution in MilliQ water by adding 10% (v/v) of the Giemsa Stain 
Modified solution 
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e.g. 50 mL Giemsa Stain Modified solution  + 450 mL MilliQ water) 
 [Note: This solution has to be freshly prepared each experiment] 
• Filter the 10% (v/v) staining solution using a 75 mm Filter Unit -500 or 1000 mL 
(Nalgene nat. number 166-0045) or equivalent 
• Remove the culture medium from the dishes aspirating it using a vacuum pump 
connected with an aspirator 
• Add 3 mL of the fixing solution into each dish and incubate at room temperature for 15 
min 
• Remove the fixing solution 
• Add 3 mL of the staining solution into each dish and incubate at room temperature for 
30 min 
• Remove the staining solution and leave the dishes to dry under the chemical hood 
overnight 
Day 9: Counting of the colonies  
• Count the number of all colonies present in each dish under a stereomicroscope.  
• Verify whether the test acceptance criteria presented below are met:  
- The colonies have to contain more than 50 cells/each 
- The number of colonies in the negative control dish have to be not less than 90 
- The plating efficiency has to be not less than 45%. The plating efficiency is 
calculated as follows: Plating efficiency = (average number of colonies in the 
negative control or solvent control) x 100 / (number of cells seeded) 
- Exposure to the positive control must result in complete cell death (no colonies in 
the dish) 
[Note: All acceptance criteria must be met for a test to be acceptable] 
 
Data analysis  
The raw data (i.e. number of colonies counted in each dish for each treatment condition and 
controls) are filled in a template provided by JRC and sent back to JRC for further analysis. 
 
IV. HEALTH SAFETY AND ENVIRONMENT 
All procedures have to be carried out under aseptic conditions and in the sterile environment 
of a laminar flow cabinet (biological hazard standard). Gloves and laboratory coat must be 
worn by operators. Only sterile equipment must be used in cell handling. Discard all the 
materials used following the appropriate procedure for special biological and chemical waste. 
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